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1.1.1 Definition and challenges 
Nanotechnology is the branch of science that investigates the potential of materials in 
nanometre range of size. The specific definition was given in 2000 by the National 
Nanotechnology Initiative: ―Nanotechnology is concerned with materials and 
systems whose structures and components exhibit novel and significantly improved 
physical, chemical and biological properties, phenomena and processes due to their 
nanoscale size‖ [1].  
Nanotechnology applied for medical purposes takes the name of ―Nanomedicine‖. 
Nano-scale devices for treatment, diagnosis, monitoring and control of biological 
system have been referred as ―Nanomedicine‖ by the National Institute of Health [2]. 
Nanomedicine aspires to develop nanoscale systems, from a few atoms to sub-
cellular size (1-1000 nm), that can reach high level of cell targeting, with minimal 










Figure 1.Research and clinical approaches of Nanomedicine. 
 
1.1.2 Nanomedicine for therapeutic application 
The successes of Nanomedicine are reported, for example, in the treatment of cancer. 
Cancer mortality counts more than 10 million new cases every year and in the past 
two years has decreased, owing to better understanding of tumor biology and 
improved diagnostic devices and treatments [3]. Ordinary cancer treatments include 
surgical intervention, radiation and chemotherapeutic drugs, and the higher 
limitations are due to low tumor specificity, low solubility and short circulation time 
of the drug. The concept of nanomedicine in therapeutic application is, thereby, 
closely related with drug-delivery. The design of an optimal nanocarrier, which 
ensures drug encapsulation, efficient cell targeting and intracellular drug release, has 
revolutionized the pharmaceutical field.  




In the recent years a lot of efforts were employed to develop the perfect delivery 
carrier for individual therapeutic agents. Careful screening of the drug, interaction 
with the carrier, binding/dissociation properties and cell uptake/cytotoxicity are 
important issues to consider for obtaining a therapeutic effect. Furthermore, blood 
stability, tolerance from the immune system and extravasation to reach a target cell 
type are included in the multitask properties that a nanocarrier, for in vivo therapy, 
should possess (Figure 2). 
 
Rational design of nanocarrier for cancer therapy 
What a nanocarrier should do What a nanocarrier should be 
Protect the drug from premature 
degradation 
Be made from a material that is biocompatible, 
well characterized, and easily functionalized 
Prevent drugs from prematurely interacting 
with the biological environment 
Exhibit high differential uptake efficiency in 
the target cells over normal cells (or tissue) 
Enhance absorption of the drugs into a 
selected tissue (for example, solid tumor) 
Be either soluble or colloidal under aqueous 
conditions for increased effectiveness 
Control the pharmacokinetic and drug 
tissue distribution profile 
Have an extended circulating half-life 
Improve intracellular penetration 
Have a low  rate of aggregation and a long 
shelf life 
 
Figure  2. Physical and chemical properties for the design of an optimal drug-delivery agent [3].  
 




1.1.3 Active and passive targeting 
In cancer delivery, the specific drug accumulation is enhanced by the disorganized 
endothelial structure and increased permeability of the endothelial barrier, besides of 
the reduced lymphatic drainage. This passive tumor targeting has been defined as 
―Enhanced Permeability and Retention (EPR) effect‖, discovered by Matsumura and 
Maeda [4]. Endothelial pores are reported to be in sizes varying from 10 to 1000 nm, 
depending on the type of tumor [5] and efficient vascular extravasation occurs with 
nanoparticles size profile lower than 400 nm [6].  
Active targeting consists, instead, in conjugating the nanoparticles with a specific 
molecule able to target a specific tissue and cell type. Proteins, peptides, monoclonal 
antibodies, small molecules, aptamers can be used to target a specific cell type [7]. 
Most of tumors up-regulates the expression of specific receptors to cope with the 
higher proliferation of malignant cells. Nowadays, the more studied over-expressed 
surface molecules are transferrin receptor, folate receptor, specific glycoproteins and 
the epidermal growth factor receptor (EGFR). Transferrin transports iron to the cells 
and folic acid is important for nucleotides synthesis. Several lectins have been found 
to specifically interact with glycoproteins expressed on cancer cells, and EGF is 
involved in proliferation, angiogenesis and metastasis [6]. Targeting tumor 
vasculature, through specific endothelial receptors, it is also possible to inhibit 
tumor-induced angiogenesis. The vascular endothelial growth factor receptors 
VEGFR-1 and VEGFR-2 are over-expressed on tumor endothelium, like αvβ3 
integrin is highly expressed on neo-vascular endothelial cells [6][8]. 
Therefore, the possibility to target tumors based on the different pattern/expression 
of specific molecules on the cell surface is becoming extremely promising. PLGA 
nanoparticles, modified with isopropyl myristate moieties, showed increased delivery 
of chemotherapeutic Paclitaxel to the lung and superior in vitro effectiveness [9]. 




Furthermore, the development of nanoparticles carrying transferrin and/or transferrin 
antibodies [10][11] and nanoparticles linked with arginine-glycine-aspartic acid 
(RGD) sequence, to target the αvβ3 integrin, demonstrated their efficiency in vivo 





Figure 3. Representative chart of the role of endothelial fenestration in enhancing passive 
transportation in the tumor microenvironment and the role of tumor targeting molecules in developing 








1.1.4 Nanomedicine in Tissue Engineering 
Nowadays, Nanomedicine is not only limited for therapeutic application, but offers 
also opportunities in regenerative medicine. The increased understanding of cell 
response to extracellular signals and the intracellular pathways involved in cell 
survival, proliferation and differentiation, inspired regenerative medicine strategies, 
with the aim to replicate biological instructions expressed during embryogenesis. 
Growth factors are the signaling molecules that instruct cells during tissue 
development, which can be studied to achieve tissue regeneration in adults. 
Encapsulation and controlled delivery of these factors may potentially activate 
specific proliferation/differentiation pathways to regenerate tissues [14][15]. 
Considering in details bone regeneration, traditional treatment methods for 
promoting bone healing include bone grafts or synthetic materials, to fill the defect 
and provide structural support. Bone autografts are considered the gold standard for 
treating bone defects, owing to the low risk of an adverse immune response, 
osteoinductive, osteoconductive, and osteogenic properties [16]. 
Recently, several growth factors have been discovered to play a role in bone 
regeneration, directly acting on osteoblasts, which produce mineralized bone matrix. 
Growth factors delivery by nanocarriers is promising for overcoming the actual 
disadvantages with conventional scaffold implantation, like immunogenicity, low 
growth factors expression and low cell proliferation. Furthermore, a nano-delivery 
system offer major control and longer-term release of the growth factor, compared to 
the direct adsorption on the surface of implanted scaffolds [17] [14]. 
Osteoblast commitment from pluripotent mesenchymal stem cells is mainly regulated 
by the growth factor family of TGF-β, with the demonstrated activity in vitro and in 
vivo of bone morphogenetic proteins (BMPs), especially BMP-2 and BMP-4, in 




guiding the differentiation process [18][19]. Besides, a number of other growth 
factors are being investigated for their potential to regenerate bone, including 
platelet-rich plasma (PRP), platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF), and fibroblast growth factor (FGF) [17].  
Osteoblast commitment involves the expression of phase-specific genes, which are 
important to evaluate the response of an ―osteogenic treatment‖. Collagen type I 
(COL1) is expressed in the early stage of osteoblast differentiation and is the main 
structural component of bone matrix. Osteopontin (OPN), a non-collagenous matrix 
protein, and alkaline phosphatase (ALP) are important in stabilizing the matrix in 
formation, and are considered early markers of osteoblasts maturation. In the late 
stage of differentiation, osteocalcin (OC) expression is up-regulated [16][20].  
Bone formation is a physiological balance between bone synthesis and bone 
resorption. Differentiated osteoblasts produce and release the cytokine RANKL, 
member of the Tumor Necrosis Factor (TNF) superfamily, that induce osteoclast 
differentiation and fusion of pre-osteoclasts [21] [22]. Therefore the activation of 
RANKL, in response to delivery agents, should be considered in order to induce 
effective osteogenesis. 
The differentiation process of osteoblasts can be divided in four stages (Figure 4): 
 
Proliferation phase: In this phase, genes required for proliferation (c-fos) and 
progression of the cell cycle (cyclins, histones) are expressed, together with genes 
associated with the biosynthesis of the extracellular matrix (COL1, TGFβ) and cell 
adhesion proteins (fibronectin). 
Matrix-maturation phase: In this phase the expression of genes involved in the 
maturation and organization of the bone extracellular matrix (alkaline phosphatase) 
are up-regulated. The role of alkaline phosphatase (ALP) is still uncertain, but since 




this enzyme cleaves phosphate groups from monophosphate-ester substrates, it is 
assumed that the enzyme is involved in bone mineralization.  
Mineralization phase. In this phase, the expression of genes associated with the 
organized deposition of hydroxyapatite (osteopontin and osteocalcin) is up-regulated. 
Apoptosis phase. In this phase were observed an increased COL1 and collagenase 
gene expression, apoptotic cell death and compensatory proliferative activity [20]. 
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Figure 4. Bone regeneration. A) Proliferation of mesenchymal stem cell (MSC) and differentiation to 
osteoblast lineage by the use of specific growth factors. B) Progressive stages of osteoblast 
differentiation with the increase in the expression or activity of phase specific markers. 
 
1.2 Drug delivery strategies 
Nowadays, the most used drug delivery strategies are lipids, inorganic materials, 
proteins and polymers, which can be strategically combined to obtain an optimal 
delivery agent.  
 
Lipids, due to their dynamic nature are easily modifiable for cell targeting, because 
their dynamic nature allows clustering of peptides or other ligands. However, their 
dynamic nature reduces the stability of the system. 
Inorganic materials (gold, carbon, and iron oxide) provide the advantage of stability; 
but the strength causes retention in the body and limited clinical application.  
Polymers offer enhanced biocompatibility and major control of drug release. 
Biodegradable polymers, like poly(lactide-co-glycolide) (PLGA), poly(lactic acid) 




(PLL-A), poly(ε-caprolactone) (PCL), chitosan, gradually release the therapeutic 
agent, with the degradation of the carrier, ensuring safe clearance of degraded 
products [12][23] (Figure 5).  
 
 





1.2.1 Impact of physical properties of nanoparticles 
It is already known that the physics of the nanocarrier influences the delivery 
efficiency, and determinant parameters, independently from the specific material, are 
grouped under ―physical targeting‖:  
Size - The size of the nanoparticles regulates uptake, clearance from the kidney and 
immune system activation [24]. Small particles inferior of 10 nm are easily excreted 
from the urinary system, while big particles or aggregation can cause vascular 
occlusion and immune response [25]. 




The size limitation for tumor targeting depends on the cut-off limit of the EPR effect 
on the endothelial barrier. Main pore size ranges between 380 and 780 nm in 
diameter, but change according with the type, location and cause of the tumor 
[26][27]. For tumor infiltration, usually small particles, around 20 nm or smaller, are 
facilitated in crossing the dense extracellular matrix [28]. 
Shape - The shape of the nanocarrier can be spherical, disk-like, rod-like, flexible 
[29] and can influence the rate of cellular uptake and body distribution [30].  
Stiffness - A clear example of how stiffness can regulate efficiency of drug delivery, 
despite of the size of nanoparticles, is given by red blood cell physiology. Red blood 
cells (RBCs), biconcave microstructures of around 8 µm, are able to deform and pass 
through small blood vessels and have inspired the development of soft polymeric 
microparticles, with the aim to simulate the same deformability. Although only few 
studies have been done in this direction, stiffness seems to regulate uptake efficiency 
in different cell lines, for example, has been reported that cervical cancer Hela cells 
can take up soft particles better than hard ones [31]. 
Charge - The surface charge is another important factor to be considered in drug 
delivery. Positive charges improve non-specific cell uptake by electrostatic 
interaction with the cellular membrane, although hydrophobic nanoparticles can 
benefit of negative charges in promoting hydrophobic contacts [32]. Positive charges 
have the disadvantage to cause in vivo aggregation with serum proteins and 










1.3 Gene therapy 
Gene therapy is a scientific discipline that has been developed with the aim of 
correcting genetic diseases. Genes are the functional units of heredity and encode 
instructions to make proteins, which regulate most of the life functions. When the 
gene sequence is altered, proteins are unable to carry their normal function and result 
in genetic disorders. Genetic medicine is applicable in the treatment of monogenic 
hereditary disorders, cancer and viral infections, with the possibility to replace a 
defective gene or introducing a new gene to confer new properties to the cell 
[34][35]. In tissue regeneration growth factors gene delivery resulted being more 
effective than protein delivery, for the possibility to overcome the unstable biological 
activity, short half-life and low tissue penetration of the growth factors [17]. The 
strategies of gene therapy include gene encapsulation in inactivated viral carrier or 
alternatively into non-viral delivery, with the incorporation of the gene sequence in a 
bacterial plasmid. Recently the discovery of RNA-modification therapy opened the 
possibility to modify the gene expression through the activation of an endogenous 
pathway, RNA interference (RNAi), which specifically blocks the translation of a 
target mRNA, through antisense oligonucleotides [36]. 
 
1.3.1 RNAi mechanism. 
Since 1998, when the researchers Fire, Mello and colleagues discovered the ability of 
double strand antisense RNA to silence the expression of a target protein, a new 
approach for gene therapy gained international attention. Synthetic double strand 
RNA sequences opened the possibility to specifically regulate the expression of a 
protein in cells and potentially reach any part of the genome. We can distinguish two 




main pathways of the RNAi mechanism (Figure 6). The first mechanism is 
physiologically activated as anti-viral response, where long double strand RNA 
sequences (dsRNA), are interpreted as pathogens by cells and degraded in the 
cytoplasm. The enzyme Dicer processes dsRNA into small interfering RNAs 
(siRNAs), which are then recognized and incorporated into the RNA-induced-
silencing complex (RISC). Argonaute2, a multifunctional protein part of the RISC 
complex, unwinds the siRNA, and mediates the degradation of the sense strand. The 
activated RISC works binding the antisense strand, using this sequence as a template 
to perfectly match the sequence of a target messenger RNA (mRNA) in the cell 
cytoplasm. RISC mediates cleavage and degradation of the target, inhibiting protein 
translation.   
The synthetic sequences, to mimic this process, are formulated to be around 21-25 
bp, skipping the Dicer functional cleavage, in order to reduce the inflammatory 
response mediated by interferon-γ (IFN-γ) [37] [36]. 
The second pathway is mediated by endogenous microRNAs (miRNAs), codified by 
the cell genome. They have been discovered to finely regulate the gene expression in 
cells, especially during embryogenesis and development [38]. miRNAs often reside 
into introns or polycistronic units in the genome and are processed in the cytoplasm 
with nearly the same mechanism of siRNAs. Different Argonaute proteins are 
involved (1-4) and the main difference in the process is the imperfect match with the 
target mRNA in sites within the 3’untranslated regions (UTRs), steric inhibition of 
mRNA translation or destabilization of mRNA by deadenylation of the poly-A tail 
[39]. 
For therapeutic application the use of siRNA is more practical and specific than 
miRNA, since miRNA can regulate the expression of multiple genes and one gene 
can be regulated by multiple miRNA.  




The gene silencing through endogenous siRNAs ensure its therapeutic effect for 3-7 
days in high proliferating cells and for several weeks in non-dividing cells [40]. 
Considering the limitations of siRNA therapeutics, siRNAs, like pDNA, do not cross 
the cellular membrane spontaneously, because of their high negative charge. The 
development of a delivery strategy is also required in order to reduce the high 
extracellular degradation and to counteract the poor targeting and high clearance by 




Figure 6. RNAi endogenous mechanisms for protein silencing: similarity and differences in siRNA 
and miRNA mechanism [36]. 




1.4 Gene delivery strategies 
Nowadays, a lot of efforts are directed to develop an efficient carrier for nucleic 
acids, to be applicable for gene and siRNA therapeutics. The two main strategies 
involve 1) engineered viruses, deprived of the genes responsible for pathogenesis, 
carrying the gene of interest and the proteins important for the transfection; 2) Non-
viral carriers, that create Wan der Walls or electrostatic interactions with pDNA or 
siRNA sequences. Viral systems ensure high transfection efficiency, but they have 
the disadvantage to provoke immune response, toxicity and mutagenesis [41]. Non-
viral carriers are preferred for the possibility to increase the safety of the gene 
delivery system for in vivo application, the possibility to insert targeting molecules, 
simple preparation and low production costs [42]. 
 
1.4.1 Viral delivery 
Viral-mediated gene delivery consists in the utilization of viruses deprived of the 
capacity to replicate, but engineered to deliver exogenous genes. The most common 
viral systems involve functional modification of adenoviruses, adeno-associated 
virus vectors, retroviruses and lentiviruses (Figure 7). These systems provide high 
delivery efficiency and a constant expression of the therapeutic gene. The major 
limitations that restrict the in vivo utilization are immunogenicity, toxicity, 
mutagenesis and limited size of DNA encapsulation [42][35]. 





Figure 7. Representative T4 Phage assembly for gene delivery. 
 
Adenovirus vectors - Adenoviruses are double strand DNA viruses, they do not 
contain lipid or membrane, and the genetic material is encapsulated in icosahedral 
particles, containing a complex combination of structural proteins. Adenovirus 
vectors can contain a relatively large amount of DNA, up of 36 kb; they cause 
receptor mediated endocytosis and do not integrate in the host genome, remaining as 
episomes in the infected cells. Therefore, the expression of the exogenous gene is 
transient. The main disadvantage of this system is the strong immune and 
inflammatory response [43].  
Adeno-associated virus vectors - Adeno-associated viruses are small single strand 
DNA viruses, with a simple protein coat. The absence of a complex envelope 
structure induces a less problematic immunogenicity compared to adenoviruses. 
They can infect cells with good efficiency and they can be engineered to persist in 




cells in an extra-chromosomal state, without integration in the host genome. The 
major limitation of these vectors is the low packaging capacity (4.5 kb)[43] [35]. 
Retroviral vectors - Retroviruses are circular-enveloped RNA viruses and they have 
the capacity to be integrated in the host genome. The infection of retroviruses is not 
cell specific and it is mediated by glycoproteins on the viral surface. Viral RNA is 
injected into cells.  
Retroviral vectors require three important genes that should be conserved in the 
engineered viral vector: ENV, POL and GAG. ENV codifies for the viral envelop, 
GAG for the viral matrix, capsid and glycoproteins and POL for the reverse 
transcriptase (RT) and the integrase enzyme (IN). RT is a viral DNA polymerase that 
converts the viral RNA in single strand DNA in the cell cytoplasm, which in the 
nucleus will be transformed in double strand DNA and integrated in the host genome 
by the integrase. The casual insertion in the genome, mediated by LTR sequences, 
causes a high risk of mutagenesis. Retroviral vectors show high transfection 
efficiency, with the capacity to deliver DNA up to 8 kb, although the transgene 
expression ceases in a range of days or weeks. The reason of the silencing is not well 
known, although the methylation of DNA into condensed chromatin seems to be 
involved [43][35][42].  
Lentiviruses - Lentiviruses belong to the family of Retroviridae.  Lentivirus vectors 
are mostly based on components of HIV1. HIV is the lentivirus responsible to cause 
chronic immune deficiency, known as acquired immune disorder syndrome (AIDS). 
Lentiviruses have a good capacity to transfect non dividing cells, as 
monocyte/macrophage lineage and neurons, with potential use for gene delivery in 
the central nervous system (CNS). Compared to retroviruses, they have a more 
complex structure, with additional regulatory genes like TAT, REV, VIF, VPR, NEF 
and VPU, to effective transfection to host cells [42]. 




1.4.2 Non-viral delivery 
The development of non-viral gene delivery carriers aims to minimize 
immunogenicity, toxicity and mutagenesis of the viral delivery system. The potential 
of non-viral delivery systems, beyond the lower toxicity for in vivo applications, is 
the possibility to link antibodies, proteins, aptamers and ligands that can confer 
specificity for a target cell type [41]. In this case the genetic material is not 
compacted into the viral nucleus, but it is incorporated in bacterial plasmids, 
commonly isolated from the bacteria Escherichia Coli. In nature, plasmids are small 
molecules that codify for some additional survival characteristics, like resistance to 
antibiotics. They consist in extra-chromosomal DNA and they can be transmitted 
from one bacteria to another one. The plasmid can replicate independently in the 
nucleus of a suitable host, exploiting the replication and transcription machinery of 
the cell. Important features, for constructing a plasmid able to replicate in 
bacterial/eukaryotic cells and express the gene of interest, are: the origin of 
replication (ORI), an antibiotic resistance gene, which allows the selection of the 
transfected cell population, a promoter and a multiple cloning site, a short region rich 
in several commonly used restriction sites, to insert the foreign gene (Figure 8).  
 






Figure 8. Representation of key characteristics of plasmids used for gene delivery. 
 
Cell delivery of genetic material, as pDNA or siRNAs, requires a non-viral delivery 
system able to promote gene transfection. Native nucleic acids are large molecules 
with negative charge, that result in poor cellular uptake and immune stimulation 
through Toll-like receptors activation [36]. Therefore, nucleic acids need to be 
compacted in small particles, which reduce the electrostatic repulsion with the 
cellular membrane, promoting cell internalization and masking the immunogenic 
nature. In the recent years, a lot of efforts have been made to improve non-viral gene 
delivery. Non-viral delivery mainly involves the formulation of cationic lipids and 
cationic polymers. The electrostatic-based condensation allows the formation of 
lipoplexes or polyplexes, in nano-scale, to be easily internalized by non-specific 
endocytosis [44].  




1.5 Non-viral delivery materials for gene therapy 
In order to efficiently describe the current strategies of non-viral gene therapy, the 
delivery methods have been divided in physical and chemical systems.  
Physical methods based their efficiency in creating transitory permeability in the 
cellular membrane. The applicability in vivo is limited for the lack of specificity, 
toxicity, for tissue damage and in most of the cases low transfection efficiency 
[41][42].  
Chemical methods group the non-viral carriers for gene delivery, commonly cationic 
lipids (Liposomes) or cationic polymers. Electrostatic interactions with 
pDNA/siRNA regulate the condensation in lipoplexes and polyplexes and the cell 
internalization exploits the physiological cell uptake mechanisms. Chemical methods 
have higher prospective for in vivo application, focusing the research efforts in 
reducing the cytotoxicity and improving selective targeting. 
 
1.5.1 Physical methods  
Microinjection - consists in the use of a micropipette to inject the genetic material 
through the cell membrane of a single cell and if necessary, through the nuclear 
envelop. This technique limits the transfection to few cells, with manipulation of 
each single cell, although allows to transfect large amount of genetic material 
without toxicity.  
Gene Gun - The DNA is encapsulated in heavy metal particles, which are accelerated 
with pressurized gas at high speed, to penetrate the cell membrane. Usually gold, 
tungsten and silver have been used. This method allows the penetration of few 




millimetres into the tissue, but tissue damage and activation of the immune response 
are the main disadvantages. 
Electroporation - uses high voltage to create transitory nanometric pores into the 
cellular membrane. This method, if optimized can reach high transfection efficiency 
that is comparable with viral systems. The major disadvantage for in vivo application 
is the large area of tissue that is subjected to the high voltage and the necessity of 
surgical operation to position the electrodes. 
Sonoporation - exploits ultrasound waves to facilitate passive gene transfection. A 
contrast agent, often air-filled microbubbles stabilized with polymers or 
phospholipids, is used to increase the permeability of the membrane of surrounding 
cells. The advantage, compared to electroporation is the safety of the method that 
does not require surgical procedures, but the transfection efficiency is low. 
Needle injection - applies the direct injection of naked DNA to tissues, organs and 
bloodstream. The method could reach high efficiency when the genetic material is 
complexed with a chemical non-viral vector, to reduce the level of extracellular 
degradation and increase the transfection efficiency. 
Jet injection:  high-speed delivery of DNA, through the use of pressurized gas, 
facilitates cell penetration into a target tissue, compared to needle-injection. The 
high-speed contact with the cell membrane creates pores that increase the 
transfection capability.  
Hydrodynamic gene transfer: hydrodynamic pressure is the driving force for 
DNA/RNA delivery into target organs. The volume of the injected solution is the 
main problem that limits the applicability in vivo, since humans cannot tolerate 
solutions equivalent to 8% of the body weight. 
 
 




1.5.2 Chemical methods  
Recently chemical non-viral vectors have been extensively studied. Condensation 
with various formulations of cationic lipids or cationic polymers has been tested, 
with particular regard to pDNA/siRNA protection, transfection efficiency, in vivo 
application and toxicity issues. 
Liposomes - are spherical vesicles composed of a single lipid bilayer, where the 
hydrophilic head groups are in contact with the aqueous environment and the 
hydrophobic tails face each other. The association with highly hydrophilic 
molecules, as pDNA and siRNA, increases with the utilization of cationic lipids, 
which contain one or more amines in the head group (Figure 9). The positive charge 
of the amino groups head group is not only necessary to incorporate the genetic 




Figure 9. Schematic incorporation of plasmids in liposomes, forming lipoplexes that can be modified 
with surface molecules for specific targeting. 
 




Typical reagents for cationic lipid transfection are N-[1-(2,3-dioleyloxy)propyl]-
N,N,N-trimethyl ammonium chloride (DOTMA), [1,2-bis(oleoyloxy)-3-
(trimethylammonio)-propane] (DOTAP), 3β[N-(N’, N’-dimethylaminoethane)-
carbamoyl] cholesterol (DC-Chol), and dioctadecylamidoglycylspermine (DOGS) 
[45]. Dioleoylphosphatidylethanolamine (DOPE) is often used, as neutral lipid, to 
improve the transfection efficiency, probably due to the conformational shift to an 
inverted hexagonal structure [45][41]. Besides, the use of cholesterol has been shown 
to increase the stability of liposomes, decreasing the probability of gene release by 
exposure to serum proteins [46]. However, the clinical application of liposomes is 
hindered by toxic-side effects, large size of the complexes and high surface charge, 
which lead to rapid renal clearance [46]. PEGylated-liposomes, with absorption or 
covalent attachment of polyethylene glycol (PEG), improve gene transfection in 
presence of serum, in vivo half-life of lipoplexes and reduced macrophage 
phagocytosis [45][46]. The property of phospholipids to fuse with the cellular 
membrane is one possibility of cell internalization, although endocytosis seems the 
major mechanism involved [41]. 
Cationic polymers - can be divided in natural and synthetic and biodegradable and 
non-biodegradable [42]. Natural and biodegradable polymers like polyamides, 
polypeptides as poly-lysine (PLL), dextran and chitosan showed comparatively low 
transfection efficiency than synthetic polymers, like branched and linear 
polyethylenimine (PEI), and PAMAM dendrimers [47][41][48]. The 
biodegradability, if in one hand ensures the safety of the delivery system, can on the 
other hand undergo through degradation in biological environment, before reaching 
the target tissue.  




Cationic polymers have the capacity to interact with nucleic acids for the high 
density of amino groups, which are protonable at neutral pH, but the high 
transfection efficiency mostly correlates with high cytotoxicity [48][49]. PEI is one 
of the most efficient cationic polymers in pDNA/siRNA delivery, but the high 
molecular weight and the high nitrogen/phosphate ratio (N/P) necessary for efficient 
transfection, cause cytotoxicity with limited application in vivo. PAMAM dendrimers 
have also shown good interaction with siRNA, with efficient ability to escape from 
endosomes, due to the internal tertiary amino groups [50]. The higher efficiency of 
PEI, compared with the other polymers, has been attributed to the higher capacity to 
escape from endosomes [41][48]. At intracellular level the ability to release 
pDNA/siRNA in the cytoplasm is of critical importance to avoid lysosomal 
degradation and has been found that endosomal escape is proportional to the 
protonable amines of the delivery agent. PLL has been demonstrated to have, at 
physiological pH, almost all the N-atoms protonated and the low transfection 
efficiency is attributed to the low capacity of activating the proton-sponge effect 
[47]. The proton-sponge effect assumes that amino group protonation delays the 
acidification that occurs during the maturation of endosomes. The ATPase proton 
pumps continue to actively translocate protons into the endosomes, which resist to 
acidification. The endosomal accumulation of protons is followed by passive entry of 
chloride ions and the ionic concentration leads to water influx. The osmotic pressure 
cause endosome swelling and wall rupture, causing pDNA/siRNA release in the 
cytoplasm [51][47]. 
PEI is partially protonated at physiological pH and the remaining amino-groups can 
be protonated in the acidic environment of endosomes, resulting more efficient in 
activating the proton-sponge effect. The importance of the phenomenon is 
demonstrated by the fact that most of the polyplexes showing low transfection 




efficiency increase their delivery capacity after co-transfection with chloroquine, a 
lysomotropic compound [47].  
For in vivo application the main concern about cationic polymers is the cytotoxicity 
and the poor circulation time, due to serum proteins and erythrocytes aggregation 
[44]. Davis et al. have recently developed the first polymer-based nanoparticle 
formulation for siRNA delivery entered in clinical trial and systemically 
administered to humans [52]. The formulation CALAA-01 is a four component 
system for siRNA therapeutics to be administered in cancer patients: a cyclic 
oligosaccharide (β-ciclodextrin) was incorporated into the backbone of linear 
polycation chains to condense the siRNA, amantane polyethylene glycol (AD-PEG) 
was used to stabilize the nanoparticles in biological fluids and human transferrin was 
adsorbed to the surface to target tumors [52][48].  
 
1.5.3 Challenges of non-viral gene delivery. 
Biological barriers and physical/chemical properties of the delivery system need to 
be considered for a therapeutic application. First, whether we consider, in vitro or in 
vivo application, the genetic material needs to be protected by extracellular 
nucleases. This point is particularly critical for siRNA delivery, because RNA is 
highly susceptible to RNAse degradation [41]. 
Secondly, the material should not aggregate with serum proteins in the bloodstream, 
it should possess a high circulation time, avoid the activation of the immune system, 
and finally cross the endothelial barrier. As discussed before, this operation is 
facilitated in case of tumor treatment, by EPR effect, but crossing the endothelium in 
presence of a healthy intima structure requires a specific uptake mechanism. The 
molecules known to be transported through endothelial cells are mainly plasma 




proteins with bloodstream transport function, like low density lipoproteins (LDL), 
very low density lipoproteins (VLDL), albumin, insulin and the iron transporter 
transferrin [53].  
Once the gene delivery system reaches the target tissue it should be able to penetrate 
into the target cell and efficiently disassemble. Important difference to be considered 
between pDNA and siRNA delivery is the intracellular site where the mechanism 
takes place: RNAi pathway entirely plays in the cytoplasm, while pDNA needs to 
further penetrate the nuclear membrane to be expressed (Figure 10). Considering that 
endocytosis is the major uptake mechanism involved in the internalization of 
nanoparticles, the delivery system requires the ability to activate endosome escape 
and intracellular release of free pDNA/siRNA molecules [54].  
 
 
Figure 10. Intracellular trafficking of nanoparticles for gene therapy. Endosome escape allows nuclear 
trafficking of DNA for gene expression and siRNA incorporation in the RISC complex for gene 
silencing. 




1.5.4 Endocytosis mechanisms 
Cell membrane is impermeable to most of the macromolecules and particles and non-
viral delivery systems have to follow specific pathways to be up-taken by cells. The 
knowledge of the uptake mechanisms and how they vary between the cell types is 
recognised, but not yet completely understood [49][55]. A part from certain types of 
liposomes, which have the capacity to fuse with the cellular membrane for their 
hydrophobic nature, most of the nanoparticles require a specific energy-dependent 
internalization mechanism [41]. Physical properties (nanoparticles size, charge, 
stiffness) and active targeting, through molecules that activate a receptor-mediated 
endocytosis, mainly regulate the uptake direction. 
Phagocytosis is an uptake mechanism mostly activated by phagocytes, like 
monocytes and macrophages, which, being part of the immune system, are 
specialized in the internalization of viruses and bacteria [49]. The other mechanisms 
are grouped under the term of pinocytosis and are distinguished in: 
macropinocytosis, clathrin-mediated pathway, caveolae-mediated pathway and lipid 
raft-mediated pathway (Figure 11). The size of the nanoparticles firstly give an idea 
of the possible internalization mechanism, although the rigid classification into size 
parameters is under discussion [47]. Clathrin-coated pits are generally large 100-150 
nm, caveolin-1 flask-shaped invagination around 50-80 nm, while macropinocytosis 
can cover big sizes of 500-2000 nm [48]. The abundance of caveolae, despite clathrin 
pits, depends on the cell type in consideration [56]. Recent studies have shown the 
ability of ―caveosomes‖, derived from multiple association of caveolae, to internalize 
big particles [57]. Microspheres with a diameter superior of 500 nm were selectively 
inhibited by cholesterol depletors, which block the internalization mediated by lipid 
rafts. Serum albumin, viruses like cholera toxin and bacteria are known to be 
internalized by caveolae-mediated endocytosis [58][59][60]. The knowledge about 




uptake mechanisms is nowadays limited and other pathways might be involved in 
regulating the uptake of macromolecules. Besides, the uptake mechanism regulates 
the intracellular trafficking of nanoparticles: clathrin-based pits are transported 
through early and late endosomes directly to lysosome to be degraded, while 
caveolae-mediated endocytosis seems to transport molecules to the Golgi apparatus, 
convenient route for pathogens to avoid lysosomal degradation [60].  
The capacity of the gene delivery carrier to escape form endosomes is particularly 




Figure 11. Schematic representation of the known intracellular trafficking pathways involved in the 









1.6 Polyethylenimine and toxicity issues. 
PEI, in linear and branched form, resulted, as described before, one of the best 
pDNA/siRNA delivery carrier, but the efficiency is critically correlated with high 
molecular weight (25kDa) and high N/P ratio required for efficient transfection, with 
toxicity issues for systemic administration [41]. PEI has been demonstrated to induce 
cell membrane damage (necrosis post-treatment) and mitochondrial-mediated 
apoptosis in a later stage, 24 hours post-treatment. Furthermore, the high positive 
charge of the polyplexes lead to nanoparticles aggregation with serum proteins and 
erythrocytes in vivo [48]. 
Linear and branched PEI showed different ability to complex pDNA or siRNAs. In 
particular, linear polyethylenimine (lPEI) resulted more efficient to complex pDNA 
than siRNA; contrarily, branched polyethylenimine (bPEI) showed good ability to 
transport siRNA, probably due to the three-dimensional structure that allows multiple 
folding options for the siRNA [51].  
Research efforts are, nowadays, focused in reducing PEI cytotoxicity, improving at 
the same time pDNA/siRNA delivery: modifications of PEI backbone and 
conjugation with neutral charged polymers or proteins are the most considered 
options for improving biocompatibility, bloodstream circulation and cell targeting 
[50]. Modification of the PEI backbone with poly-ethylene glycol (PEG) has been 
already demonstrated to reduce non-specific localization in liver, spleen and lung, 
compared to the PEI polyplexes. However, the uptake efficiency by cells resulted 
low for the dramatic reduction of the surface charge [61].  
A lot of efforts are nowadays directed to functionalize PEI structure: amino groups 
acetylation, succinylation, alkylation are proposed for improving siRNA-
therapeutics, reducing toxic side effects [50] (Figure 12). Moreover, the oxidation of 




the amino groups of PEI with hydrogen peroxide (H2O2) showed reduced 
cytotoxicity of PEI-DNA polyplexes, without compromising, although increasing 




Figure 12. Functionalization of bPEI by acetylation, succinylation, PEGylation and modification with 
hydrophobic choresterol, long alkyl chains and PBLG chains for decreasing the cytotoxicity, 
increasing the stability of polycation complexes and prolonged blood circulation time [50]. 
 
Besides the structural modifications, the conjugation of PEI with ―cell-targeting 
ligands‖, as serum proteins or macromolecules, have been tested. The conjugation 
with cholesterol and long alkyl groups, for example, can increase the possibility to 
target the liver by interacting in vivo with the high-density lipoprotein (HDL) and 
low-density lipoprotein (LDL) receptors [37]. More recently, the conjugation of PEI 




with galactose has been investigated to increase a receptor-mediated endocytosis in 
hepatocytes [48].  
PEI conjugation with transferrin (Tf), epithelial growth factor (EGF) and folic acid 
was studied for the possibility to target cancer, considering that tumor cells over-
express their receptors. Ogris et al., have demonstrated that PEI conjugated with 
transferrin, improves gene transfection in human erythromyeloid leukemia cells, 
compared to unmodified PEI polyplexes [63]. 
  
1.7 Active targeting: the potential of albumin. 
Serum proteins have been recently discovered to serve as endogenous targeting 
ligands and for increasing nanoparticles circulation, after injection [44][53]. In Kim 
et al., have reported that apolipoprotein A-I, a component of the high density 
lipoprotein (HDL), can be assembled with liposomes to address siRNA delivery to 
the liver, through specific receptor-mediated internalization in hepatocytes [64]. 
Transferrin, the iron transporter in the bloodstream, in the recent years has been 
largely employed for non-viral gene therapy, as the cited CALAA-01 siRNA-
therapeutic agent and PEI-Tf-DNA complexes. The future direction of genetic 
medicine is, therefore, direct the therapeutic agent to the target cells, ensuring a good 
transfection efficiency, which translates in high therapeutic effect.  
Nowadays, plasma proteins are gaining attention for the possibility to increase the 
half-life of a therapeutic agent and the possibility to target tumors, due to the EPR 
effect. Serum proteins, as transferrin, albumin, LDL are promising as anti-neoplastic 
agents [53].  
Human serum albumin (HSA) is the most abundant protein in human plasma and it 
transports a broad range of molecules in the bloodstream: fatty acids, therapeutic 




drugs (aspirin, penicillins, benzodiazepines), metabolites and metal ions (copper II, 
nickel II, calcium II, zinc II) [53]. 
HSA has been discovered to accumulate in malignant tumors and inflamed tissues 
and the therapeutic application as drug delivery carrier has been validate with the 
commercialized agent Abraxane (ABI-007) [65]. Abraxane consists in paclitaxel 
albumin-loaded nanoparticles, which improves the anticancer therapeutic efficiency 
of paclitaxel in the treatment of metastatic breast cancer. Other types of malignant 
tumors have been tested for the therapeutic efficiency of Abraxane, for example head 
and neck cancer [66].  
A recent study has demonstrated the role of albumin in preventing non-specific 
protein absorption to nanoparticles in presence of serum, with potential to enhance 
nanoparticles circulation time [67]. Moreover, it is known that albumin, further being 
transported to tumors by EPR effect, possesses the ability to actively cross the 
endothelial membrane by gp60 receptor- mediated transcytosis [56][68][69]. The 
internalization of HSA has been demonstrated to involve caveolae-mediated 
endocytosis in endothelial cells [56]. 
In the intra-tumor environment the secreted protein acidic and rich in cysteine 
(SPARC) has been shown to have a role in binding albumin, facilitating the 
transportation in tumor cells, to probably being used as source of amino-acids and 
energy [70]. SPARC and gp60 share a region of structural homology, which is 
associated with the common albumin binding activity [71].The over-expression of 
SPARC and caveolae in many malignant tumors have been correlated with high 
tumor invasion and metastasis [66][72].  
Therefore, many advantages could derive from the use of albumin as gene delivery 
carrier, including high circulation time in the bloodstream, tolerance from the 
immune system and tumor targeting. 
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2 Outline of the Thesis 
 
The overall aim of this thesis is to improve branched polyethylenimine (bPEI) 
delivery system for gene therapy application. As previously discussed in the 
introduction, despite the good efficiency in condensing nucleic acids and promoting 
cell transfection, the major limitation of PEI for in vivo application is the high 
cytotoxicity, due to the high positive charged amino groups density.  
The effect of amino groups acetylation on bPEI backbone and the incorporation of 
human serum albumin (HSA) in bPEI-siRNA polyplexes have been investigated to 
improve cell transfection efficiency and reduce the toxicity that accompanies the 
delivery efficiency. 
Firstly, my project was focused in investigating the effect of partial acetylation of 
primary amino groups, along PEI backbone, in the capacity to form nanoparticles 
(NPs) with poly(lactic-co-glycolic acid) (PLGA), the influence of acetylated PEI 
(AcPEI) in nanoparticles size and surface charge and the ability of NPs to deliver 
genetic material. Particular attention was paid in testing cell cytotoxicity, 
genotoxicity and immunotoxicity, following transfection of both PEI-PLGA (PEI-
NPs) and AcPEI NPs, with the aim to increase the biocompatibility of the system for 
in vivo applications. Nanotoxicity is often underestimated, but it is of fundamental 
importance for therapeutic use. Considering the application of NPs as medical 
devices, collateral effects as inflammation, immunoreaction, or cancer, can emerge 
due to NPs toxicity. Free oxygen radicals production, following cell stress and 
immune system activation, can contribute in the risk of DNA mutation and cancer. 
Therefore we concentrated our work in studying PEI-NPs capability of promoting 




DNA damage and intracellular ROS release, investigating the potential of AcPEI-
NPs, with 50% of acetylated amino groups, in reducing the toxicity of PEI, without 
compromising the transfection efficiency. 
After having demonstrated the effectiveness of AcPEI gene delivery system in 
human umbelical vein endothelial cells (HUVEC), we focused our study on the 
possibility to use acetylated PEI nanoparticles as gene delivery carrier in tissue 
engineering. In this study, the internalization efficiency, the mechanism of uptake 
involved and the endosome escape efficiency were investigated in human primary 
osteoblasts (hOBs), isolated from human trabecular bone. The cytotoxicity was 
evaluated in terms of membrane damage (necrosis) or activation of apoptosis, while 
the effect of the nanoparticles on hOB activity and differentiation was studied 
quantifying alkaline phosphatase (ALP) activity, collagen type I production (COL1), 
mineralization and gene expression of markers of differentiated osteoblasts. The 
results will be used for future application of these nanoparticles in gene delivery to 
promote osteogenesis and in siRNA delivery to inhibit bone formation in blood 
vessel walls. 
The project, developed at the University of Freiburg, involved the incorporation of 
human serum albumin (HSA) into pre-formed bPEI-siRNA polyplexes, with the aim 
to improve transfection efficiency in the tumor microenvironment, since HSA has 
been demonstrated to accumulate in inflamed tissues and tumors [65]. The ternary 
complex, formed by electrostatic interactions, was characterized in terms of size and 
surface charge. The intracellular delivery efficiency, mechanism of uptake and 
silencing efficiency were evaluated with in vitro studies, investigating a direct role of 
HSA in promoting cell uptake and gene silencing, compared to bPEI-siRNA 
complexes. Further studies will be focused in investigating a possible HSA receptor 




mediated endocytosis of the complexes, for HSA utilization as a tumor targeting 
molecule.  
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3.1 Summary 
The ultrasmall size and unique properties of polymeric nanoparticles (NPs) have 
led to raising concerns about their potential cyto- and genotoxicity on biological 
systems. Polyethylenimine (PEI) is a highly positive charged polymer and is 
known to have varying degree of toxic effect to cells based on its chemical structure 
(i.e., amount of primary and secondary amine). 
Herein, drug delivery carriers such as PEI-PLGA nanoparticles (PEI-NPs) and 
acetylated PEI-PLGA nanoparticles (AcPEI-NPs) were utilized to examine the 
effect of acetylation on NPs biocompatibility and genotoxicity, using human 
primary cells as in vitro model. 
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Cell uptake of NPs was characterized along with their effects on cellular viability. 
The results indicate that both NPs showed an equivalent behavior in terms of uptake 
and biocompatibility. In depth analysis of NP uptake on cell biology evidenced that 
these nanoparticles induced dose dependant genotoxic effects. This phenomenon 
was significantly reduced by PEI acetylation. Endocytosed PEI-NPs trigger an 
oxidative stress on cells by inducing the production of reactive oxygen species 
(ROS), which cause DNA damage without apparently affecting cell viability. Thus, 
the genotoxicity of nanoparticles that could be used as non-viral drug carriers, 
should be evaluated based on the intracellular level of ROS generation and DNA 
damage even in absence of a significant cell death. 
 
3.2 Introduction 
In the last decades it is increased the interest in the development of drug delivery 
systems, with special emphasis on the design and fabrication of delivery platform for 
cancer treatment and regenerative medicine. In general, these delivery systems are 
engineered to minimize drug degradation upon administration, prevent undesirable 
side effects, and sustain and/or increase drug’s bioavailability in the targeted area. 
More recently, several studies took advantage from basic chemistry to obtain 
structurally simple materials, where the topography and nanoscale dimensions are 
crucial to promote cell interactions mediating intracellular drug delivery [1][2]. 
Indeed, engineered nanomaterials possess distinct physicochemical properties as a 
result of their nanometre-scale size, increased surface area, variable chemical 
composition, surface structure, and shape [3]. Although impressive from an 
applicative point of view, the novel properties of nanomaterials can generate adverse 
effects on biological systems, since their size increases the possible interactions at 
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the cellular, subcellular, and protein levels [4]. In addition, some conventional 
nanomaterials that are used in biomedical and pharmaceutical applications have also 
exhibited considerable toxicogenomic effects. A study of DNA delivery systems 
comprised of common transfection agents (i.e., lipofectamine and oligofectamine), 
revealed marked changes in the expression of several genes in epithelial cells [5]. In 
another study, it was shown that the polycationic polyethylenimine (PEI), formulated 
with plasmid DNA and administered to mouse lungs, activated p38 pathway 
involved in endocytosis, phagocytosis and hydrogen peroxide production [6]. The 
considerable toxicity of such PEI polyplex formulations observed in vitro and in vivo 
was, therefore, linked to a general oxidative stress reaction leading to inflammatory 
responses, cell cycle dysregulation and DNA damage. 
Clearly, analysis of toxicogenomic responses of new polymers and nanomaterials 
along with conventional assessment of their toxicity in animal models is now 
becoming essential for development of safe pharmaceutical formulations with wide 
therapeutic index and low toxicity profiles [3] It is therefore imperative that direct 
effects on DNA must be examined to provide preliminary information on the 
potential genotoxicity of nanomaterials. 
However, while the cytotoxicity of specific nanoparticles (NPs) traditionally 
evaluated by determining the extent of cell survival after exposing NPs to cells, has 
shown reproducible results, there are only some conflicting evidences about the 
genotoxicity of the same NPs. Since the genotoxicity behavior of NPs is quite 
distinguished from bulk materials, there is an urgent call for the establishment of 
principles and test procedures to ensure the safety of NPs. Taking into account that 
the cytotoxic and genotoxic potential of a nanomaterial is most likely dependent on 
chemical properties, we have synthetized and biologically tested PEI-based 
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copolymers modified or not by the addition of acetyl groups to amines in the PEI 
backbone [7]. 
Bearing in mind that in vitro tests involving nanoparticulate systems represent a key 
aspect of current investigations on clinical applications of nanomaterials, we 
evaluated the genotoxicity of PEI-NPs using human primary cells as targetable 
cellular models. We evaluated also if acetylated PEI-NPs may represent an effective 
alternative to classical PEI-NPs for intracellular DNA delivery. 
 
3.3 Materials and Methods 
Cell culture and materials 
 
Human umbilical vein endothelial cells (HUVEC) were from Life Technologies 
(Italy) and cultured in accordance with the manufacturer’s instructions. Branched 
polyethylenimine (PEI, MW: 25 kDa), poly(vinylalcohol) (PVA), acetic anhydride, 
5,5-dimethyl-pyrroline N-oxide (DMPO), phenyl N-tert-butylnitrone (POBN), 
dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), 2,4,6- 
trinitrobenzenesulfonic acid (TNBS), D2 O, coumarin-6, etoposide, dimethyl 
sulfoxide (DMSO), phytohemagglutinin (PHA), bromodeoxyuridine were obtained 
from Sigma Aldrich (Italy). Dialysis membranes (molecular weight cut off 3500 Da) 
were from Spectrum Laboratories. d,l-Lactide/glycolide copolymer (PLGA, 
PURASORB® , inherent viscosity 0.20 dl/g) was a generous gift from PURAC 
(Gorinchem, The Netherlands). Endonuclease III (Endo III) and 
formamidopyrimidine-DNA glycosylase (Fpg) were from New England Bio-Labs 
(United Kingdom). Lactate dehydrogenase (LDH) Release Assay and WST-1 reagent 
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were from Roche Applied Science (Milan, Italy). phMGFP plasmid, PureYieldTM 
Plasmid Maxiprep System, 1-kb DNA ladder and 6× DNA loading buffer (30% 
glycerol, 125 mM EDTA, 0.25% bromophenol blue and 0.25% xylene cyanol) were 
from Promega (Milan, Italy). 
 
Preparation of nanoparticles 
 
Polyethylenimine 25 kDa was acylated using acetic anhydride as reported earlier 
[8][9]. The modified polymers were characterized by 1 H-NMR in D2O and FTIR. 
IR (KBr) v (cm−1): 3437 (amino stretching), 2932, 1638 (carbonyl stretching). The 
extent of acetylation was determined 
through quantification of the free amino groups remaining on the polymer following 
2,4,6-trinitrobenzenesulfonic acid (TNBS) method [10]. The extent of acetylation of 
PEI was also confirmed by 1 H NMR [9]. 
Copolymer composed of branched PEI or acetylated PEI (AcPEI) and PLGA were 
prepared using a two-step procedure. First, PLGA was activated by DCC and NHS, 
then PEI or AcPEI were reacted with activated PLGA at a PLGA:PEI molar ratio of 
3:1. Nanoparticles of PEI-PLGA and AcPEI-PLGA copolymer were prepared 
directly from the reaction solution by using emulsion-solvent-evaporation method. 
Briefly, the reaction was stopped after 3 h by ice cooling, and a mixed solution of 
acetone and dichloromethane was added to 100 ml of 1.0% (w/v) PVA aqueous 
solution, and emulsified using a probe sonicator (Digital Sonifier S-250D, 
BRANSON) at 200 W of energy output for 5 min on ice bath. The emulsion was 
stirred overnight on a magnetic stir plate to allow organic solvents to be evaporated 
and then dialyzed against distilled water for 2 days. PEI-PLGA or AcPEI-PLGA 
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nanoparticles (PEI-NPs and AcPEI-NPs) were obtained after lyophilization on a 
speed vac. 
Coumarin-6-loaded nanoparticles were prepared with the same procedure except that 
0.01% (w/v) of coumarin-6 was added to the dichloromethane/acetone mixture 
before emulsification. In addition, the coumarin-6 loaded nanoparticles were 
subjected to a 1.5 cm × 20 cm sepharose CL-4B column (Pharmacia Biotech) eluted 
with 0.05 M HEPES buffer (containing 0.15 M NaCl, pH 7.0) to remove the non 




Dynamic light scattering (DLS) with a Zetasizer Nano ZS90 instrument (Malvern 
Instruments, Worcestershire, UK) was used to measure the diameter and zeta 
potential of the nanoparticles. The hydrodynamic diameter of the freshly prepared 
PEI-NPs and AcPEI-NPs was measured at 25 ◦C with a scattering angle of 90◦ (10 
mW He–Ne laser, 633 nm), and the zeta potential was determined by the standard 
capillary electrophoresis cell of Zetasizer Nano ZS at position 17.0 and at 25 ◦C. 
Polystyrene nanospheres (220 ± 6 nm and −50 mV) were used to verify the 
performance of the instrument. All the average values were performed with the data 
from six separate measurements. Arithmetic mean and standard deviation were 
calculated from six consecutive runs, and samples were analyzed using Malvern PCS 
software. To evaluate if a fluorescence probe remained associated with the particles 
during a 24 h incubation period, the in vitro release of coumarin-6 from the 
nanoparticles was investigated under sink condition. Coumarin-6-loaded PEI-NPs 
and AcPEI-NPs were incubated at 37 ◦C in pH 4 and pH 7.4 in PBS, which 
represented the pH in the endo-lysosomal compartment and physiologic pH, 
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respectively, at a coumarin- 6 concentration of 50 ng/ml with a shaking rate at 100 
rpm. Periodic samples were subject to centrifugation at 21,000 × g for 45 min and the 
supernatant was further diluted with methanol and analyzed for the released 




All assays were carefully established to avoid nanoparticle-induced interferences. 
Cells were seeded in 96-well format and then treated with nanoparticles (PEI-NPs 
and AcPEI-NPs) in concentrations of 5–300 µg/ml for 24 h of incubation. The stable 
tetrazolium salt WST-1 is cleaved to a soluble formazan by a cellular mechanism that 
occurs primarily at the cell surface. This bioreduction is largely dependent on the 
glycolytic production of NAD(P)H in viable cells. Therefore, the amount of 
formazan dye formed directly correlates to the number of metabolically active cells 
in the culture. For the WST-1 assay, WST-1 tetrazolium salt reagent (Roche, Italy) 
was added and after 3 h of incubation, supernatants were transferred into vials, and 
centrifuged with maximum speed at room temperature in a table-top centrifuge 
(Eppendorf, Italy) to remove interfering particles (16,800 × g). After centrifugation, 
spectrophotometric readout was performed. Two positive chemical controls were 
included (1 mM hydrogen peroxide and 200 µM glutamate). 
LDH assay is based on the measurement of lactate dehydrogenase (LDH) released 
into the growth media when the integrity of the cell membrane is lost. For this assay, 
the supernatant was removed, centrifuged, and analyzed with LDH assay kit (Roche, 
Italy). As a positive control, cells were completely lysed with Triton X-100 
according to the manufacturer’s instructions [13]. Proliferation of the cells treated 
with nanoparticles was determined by trypan blue exclusion. Briefly, a 0.5 ml aliquot 
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of cell suspension was mixed with 0.5 ml of 0.4% trypan blue dye and left for 5 min 
at room temperature. Cell number was counted on a hemocytometer and the 
proliferation indexes (N/N0, where N is the total number of cells at T = 24 or 48 h 
and N0 is the number at T = 0) was determined. 
 
Quantitative uptake of coumarin-6-loaded PEI-NP and AcPEI-NP 
 
HUVEC cells were seeded at a density of 105 cells/cm2 onto 24-well plates. On the 
second day, the cells were pre-incubated with Hank’s buffered salt solution 
(Hyclone, Italy) for 15 min, and the medium was replaced with the suspension of 
nanoparticles (5–300 µg/ml) and incubated for 1 h at 4 ◦C and 37 ◦C, respectively, to 
study the effect of  incubation  temperature  on  nanoparticle  uptake.  In  a  separate 
experiment, to study the effect of incubation time on nanoparticle uptake, the 
medium was replaced with 1 ml (50 µg/ml) suspension of nanoparticles in HBSS per 
well and the plate was incubated for 15 min, 30 min, 1 h, 2 h and 4 h at 37 ◦C, 
respectively. Then the cells were washed with ice-cold PBS for 5 times and 
solubilized in 400 µl 1% Triton X-100. Cell lysates were subjected to BCA protein 
assay, lyophilized and used for HPLC analysis of coumarin-6 after methanol 
extraction. A standard curve of  nanoparticles  was  constructed  by  suspending 
different  concentrations  of nanoparticles (6–1200 ng/ml) in 1% Triton X-100 
followed by lyophilization and extraction of coumarin-6 in methanol. The uptake of 
nanoparticles by HUVEC cells was calculated from the standard curve and expressed 
as the amount of nanoparticles (µg) uptaken per mg cell protein [12]. 
 
Transfection in vitro 
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We carried out experiment on HUVEC cells, since they are among the hard to 
transfect cell types [14]. In order to evaluate the transfection efficiency of the NPs in 
vitro, complexes of nanoparticles and plasmid DNA (1 µg of phMGFP encoding 
green fluorescent protein, Promega, Italy) were formed by first diluting plasmid and 
the appropriate amount of nanoparticles separately with 150 mM NaCl, pH 7.4, to 
equal volumes. The nanoparticles suspension was then added to the phMGFP 
plasmid solution, vortexed immediately at room temperature and allowed to stand for 
30 min to attain complexes (PEI-NPs/DNA and AcPEI-NPs/DNA). 
For phMGFP transfection, cells were seeded in 24-well plate at a density of 1 × 105 
per well in medium with 10% FBS. The day after, cells reached 50–70% confluence 
and the medium in each well was replaced with 0.4 ml of fresh serum-free medium, 
and 0.1 ml serum-free medium containing naked plasmid DNA, PEI- NPs/DNA or 
AcPEI-NPs/DNA complex at different nanoparticles/DNA weight ratios and 
incubated for 4 h under standard incubator conditions. After 4 h, the medium was 
replaced with 0.5 ml of complete medium and incubated until 24 h post transfection. 
The analysis of transfection efficiency was performed using a flow cytometer (FACS, 
BD Biosciences, USA). The percentage of cells expressing the green fluorescent 
protein (GFP) was than determined from 10,000 events, and reported as a mean ± 




HUVECs were suspended in low melting point agarose in PBS, pH 7.4 and the cell-
agarose suspension was pipetted onto a frosted glass microscope slide pre-coated 
with a layer of normal melting point agarose. Subsequently, each slide was lysed for 
1 h at 4 ◦C in lysis solution (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris, 1% N- 
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lauroylsarcosine, 1% Triton X-100 and 10% DMSO added prior to use, pH 10.0). 
The slides were then placed in an electrophoresis tank containing 0.3 M NaOH and 1 
mM sodium EDTA pH > 13.0 for 40 min of alkali denaturation, before 
electrophoresis at 20 V for 30 min at 4 ◦C. The slides were neutralized by rinsing in 
neutralizing buffer (0.4 M Tris–chloride, pH 7.5) for 20 min at 4 ◦C. The slides were 
finally stained with ethidium bromide (20 µg/ml) for the visualization. Dimethyl 
sulfoxide (DMSO, 1%) was used as negative control and etoposide (0.5 µg/ml) as 
positive control. One hundred images were randomly selected from each sample and 
the comet tail DNA (tail DNA %) was measured. Each experiment was repeated two 
times. The percentage tail DNA is positively correlated with the level of DNA 
breakage or/and the number of alkali-labile sites and is negatively correlated with the 
level of DNA cross-links in the alkaline version of the comet assay [15]. The mean 
value of the tail DNA % in a particular sample was taken as an index of the DNA 
damage in this sample. 
 
Oxidative modifications to the DNA bases 
 
We carried out a modified Comet assay to detect oxidized purines and pyrimidines 
[16]. The cell-agarose suspension slides were prepared as described above for the 
standard comet assay. After lysing, the slides were incubated at 37 ◦C for 30 min 
with (i) endonuclease III (Endo III, 1:1000, 30 min), (ii) formamidopyrimidine-DNA 
glycosylase (Fpg, 1:1000, 45 min) and (iii) with enzyme buffer (control). Endo III 
recognizes oxidized pyrimidines while FPG recognizes oxidized purines, specifically 
8-oxo-guanine. The slides were electrophoresed and analyzed as above reported. 
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Reactive oxygen species (ROS) detection 
 
Intracellular ROS levels were investigated by measuring the oxidative conversion of 
21, 71 -dichlorofluorescin diacetate (DCFH-DA) to the fluorescent compound 
dichlorofluorescin (DCF, Molecular Probes, Milan, Italy) as published elsewhere 
[17]. Cells were exposed to increased concentration of nanoparticles (5–300 µg/ml) 
for 24 h, washed twice with PBS, and incubated 30 min at 37 ◦C with 80 µM H2 -
DCF-DA. They were then harvested by scraping, centrifuged, and resuspended in 
PBS. High DMEM culture medium was used as a negative control. Hydrogen 
peroxide was used as a positive control to validate the protocol. The fluorescence 
intensity of cell suspensions was measured with excitation at 480 nm and emission at 
530 nm (Molecular Devices, Gemini X fluorescence spectrophotometer, USA). 
 
Effects of nanoparticles on cytokine production in peripheral blood cells 
 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers. 
Peripheral human blood samples, containing sodium citrate 3.8% solution as 
anticoagulant agent, were centrifuged in Lymphoprep gradient at 2000 × g for 20 
min. The obtained PBMCs were diluted in PBS and centrifuged at 1200 × g for 10 
min. The isolated cells were resuspended in PBS, plated at 7 × 104 cells/well in a 96-
well plate and used to test NPs effect on cytokine production. PBMCs activation was 
evaluated using a sandwich ELISA kit that allows to perceive and semiquantify the 
released proteins (Human Cytokine Antibody Array-Panomics, Affymetrics, USA). 
Briefly, the media of PBMCs cultured with the 300 µg/ml NPs, were incubated with 
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the array membrane where capture antibodies, specific to particular cytokine 
proteins, are immobilized. 
Then a detection biotin-conjugated  antibody  binds  to  a  second  epitope on the 
protein, creating an antibody ―sandwich‖ around the cytokine. After streptavidin–
HRP incubation, membranes were analyzed using a VersaDoc Imaging System 




A statistical analysis of data was carried out using the SPSS for Windows software. 
Multiple comparison of data was performed using one-way analysis of variance 
(ANOVA), Bonferroni’s t-test was applied to evaluate differences in the trend of the 
measured parameters. P-value was obtained from the ANOVA table and the 
conventional 0.05 level was considered to reflect statistical significance. 
 
3.4 Results 
Synthesis and characterization of nanoparticles 
 
To investigate the effects of acetylation on the polymer toxicity, we modified 
commercially available high molecular weight branched 25 kDa PEI through the 
addition of acetyl groups to amines in the polymer backbone. To determine the 
extent of acetylation, PEI and AcPEI were dissolved in D2O and H-NMR spectra 
were acquired (Suppl. Figure 1). The extent of primary and secondary amine 
acetylation was determined by peak integration as reported by Gabrielson and Pack 
[18]. The reactions produced PEI with 35.6 ± 0.5% and 52 ± 1.4% (AcPEI36 and 
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AcPEI52), respectively of their primary amines acetylated as confirmed by TNBS 
method. The reduction in concentration of primary amines decreases the 
concentration of protonable nitrogens of PEI, which might affect DNA binding and 
hence, toxicity and transfection. Supplementary data associated with this article can 
be found, in the online version, at http://dx.doi.org/10.1016/j.toxlet. 2012.12.019. 
Particle size and zeta potential have been demonstrated to play important roles in 
determining the effect on the cell toxicity. Moreover, the measures of size, 
polydispersion and zeta potential of particles are parameters indicative of their 
stability in suspension. Size distribution of nanoparticles was assessed using dynamic 
light scattering (DLS) after dispersion in deionized water (Table 1). The size of the 
nanoparticles was not affected by PEI acetylation since it was between 90 and 105 
nm for all PEI-NPs and AcPEI-NPs preparations examined, with a polydispersion 
index lower than 0.2. The zeta potential values were found to decrease with the 
increase in the degree of acetylation, which is consistent with the decreased 
percentage of available amino functions in the nanoparticles (Table 1). 
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Table 1. Size distribution and zeta potential of the nanoparticles 
 
 
Values represent nanoparticles population range. The subscript of AcPEI indicates the percentage of 
acetylated primary amines. 
 
Nanoparticles cellular uptake 
 
To evaluate quantitatively the cellular uptake and kinetic internalization of the PEI-
NPs and AcPEI-NPs further, the effects of various concentrations of coumarin-6-
labeled nanoparticles and different incubation times were investigated in HUVEC 
cells (Figure 1). As reported in Figure 1A, a concentration-dependent increase in the 
cell-associated fluorescence intensity was observed in cell after 4 h of incubation, 
showing almost a first order kinetics. It can be clearly observed that the efficiency of 
nanoparticles uptake by cells was higher at lower nanoparticles concentration, while 
it decreased at greater concentration, which indicates the saturated and limited 
capability of cellular uptake of the nanoparticles (Figure 1A). There were no 






PLGA 62 ± 1.7 0.12 ± 1 −20.5 ± 0.3 
PLGA-PEI (PEI/NPs) 90 ± 1.6 0.15 ± 1.6 26.5 ± 1.6 
PLGA-AcPEI36 
(AcPEI36 -NPs) 
105 ± 1.5 0.18 ± 0.4 24.1 ± 1.5 
PLGA-AcPEI52 
(AcPEI52 -NPs) 
110 ± 2.8 0.16 ± 1.2 18.1 ± 1.9 
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statistically significant differences in cell-associated fluorescence between AcPEI36-
NPs and AcPEI52-NPs (p > 0.05).The nanoparticle uptake was also dependent on the 
incubation time. The uptake was seen as early as at 15 min, which increased 
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Figure 1. Cellular uptake of coumarin-6-loaded PEI/NPs and AcPEI/NPs at (A) different 
concentrations incubated at 37 ◦C and 4 ◦C for 4 h, and (B) for different incubation periods of time at 
50 µg/ml. Cell-associated fluorescence was calculated from the standard curve and expressed as the 
amount of nanoparticles (µg) uptaken per mg cell protein. Results are expressed as the mean of three 
independent experiments ± standard deviation (n = 3–4). 
 
 
Recent papers have demonstrated that less than 0.6% of the incorporated coumarin-6 
could leach out from the nanoparticles over 48 h under in vitro sink conditions, and 
that the raw coumarin-6 cannot be directly internalized by the cells . Thus, the 
fluorescence measured from our uptake experiments reflects the fluorescent 
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In vitro gene expression assay 
 
The uptake experiments evidenced that acetylation of PEI did not modify the 
internalization of NPs, then we decided to evaluate the effect of acetylation on the 
PEI’s ability to promote cellular DNA uptake. It is clear that cell transfection is 
dependent on DNA/vector uptake efficiency. HUVEC cells were transfected in vitro 
with 1 µg of plasmid DNA complexed with polymer at different nanoparticles/DNA 
weight ratios (w/w) ranging from 5 to 30. Gene transfer efficiency was measured and 
evaluated for their transfection efficiency in cells by using FACS in absence (Figure 
2A) or presence (Figure 2B) of serum. AcPEI-NPs showed transfection efficiency in 
a dose dependent manner while PEI-NPs reached optimum at PEI-NPs/DNA weight 
ratio 10 and further decreased till PEI-NPs/DNA weight ratio 20. This is undoubtedly 
because of the toxicity of PEI-NPs at high concentrations where AcPEI-NPs 
remained much efficient because of their significant low toxicity. 
These data strongly suggest that the transfection efficiency of AcPEI-NPs is superior 
to that of PEI-NPs. Based on these results, we decided to use AcPEI52-NPs in all the 
following experiments, unless otherwise specified. 
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Figure 2. In vitro gene transfection efficiency of PEI/NPs and AcPEI/NPs at various 
nanoparticles/DNA weight ratios in absence (A) and in presence (B) of serum. Data are the mean ± 
SD of four separate experiments. As control we used PEI without PLGA copolymerization (PEI). *p < 
0.05 compared with PEI. 
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Cellular nanoparticles toxicity: in vitro assessment 
 
The uptake and transfection experiments suggested that AcPEI- NPs were more 
effective as DNA transfection agent than PEI-NPs. So, we decided to carry out in 
depth analysis on cyto- and genotoxicity of such compounds to evaluate if they could 
be considered a valid alternative as drug carrier. NP-dependent effects on cell 
viability and cytotoxicity were assessed after 24, 48 and 72 h of incubation by 
applying the WST-1 and the LDH assays in parallel. Both toxicity assays were 
optimized to reduce potential particle interferences and both produced similar results 
(Figure 3A and B). No decrease of cell viability was observed on the cells tested 
after 24, 48 and 72 h of incubation with AcPEI-NPs added at 5, 50, and 300 µg/ml. 
Then, we examined the effect of various concentrations of PEI-NPs and AcPEI-NPs 
on cell proliferation. Cell proliferation indexes (N/N0) were assessed by cell 
counting and  trypan  blue  exclusion assays [19]. In control conditions, cell number 
increased at 24 h (N/N0 = 1.1 ± 0.03) and 48 h (N/N0 = 2.3 ± 0.19). When cells were 
cultured with PEI-NPs and AcPEI-NPs, no significant change in the proliferation rate 
was observed even when very high PEI-NPs concentrations were added to culture 
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Figure 3. Cytotoxicity of the nanoparticles tested via LDH (A) and WST-1 (B) assays after 24, 48 and 
72 h of incubation. In each experiment, four replicates per concentration were tested. The experiment 
was repeated three times. The data shown are mean values of three independent experiments (±SEM). 
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The genotoxicity of nanoparticles prepared with PEI (and its formulation 
components) have been little studied, although this polymer is one of the most 
widely used in the preparation of polymer nanoparticles. Studies of the impacts of 
these nanostructures on living organisms and on the environment are therefore 
needed so that the safety of these nanosystems can be assessed before they become 
even more widely commercialized. The literature describes several assays that can be 
used to determine genotoxicity in polymeric nanostructured systems, including 
assays involving plants such as the Allium cepa chromosome aberration test [20][21] 
single- and double-strand breaks (SSB and DSB), and alkalilabile sites (ALS). The 
general trend was that PEI-NPs caused a concentration-dependent increase in the 
percentage of tail DNA in the alkaline version of the comet assay. The increase was 
three times for the highest PEI-NPs concentration (300 µg/ml, p < 0.05). No changes 
in the percent tail DNA was observed with AcPEI-NPs at the same PEI-NPs 
concentration, which indicates that AcPEI-NPs did not introduce DNA-strand breaks 
in HUVEC cells. 
We carried out also an alkaline Comet assay using lesion-specific enzymes to detect 
oxidized pyrimidine and purine to evaluate if the observed DNA damage induced by 
PEI-NPs treatment is related to oxidative events. In order to identify the oxidative 
damage, two repair-specific enzymes (ENDO III and Fpg) that recognize and cut 
oxidized DNA bases were employed. Figure 5 shows DNA damage of HUVEC 
exposed to PEI-NPs or AcPEI-NPs followed by post-treatment with Endo III and 
Fpg for 1 h, compared with cells without treatment with these enzymes. DNA from 
HUVEC incubated with the highest concentration of PEI-NPs and treated with Endo 
III or Fpg showed a significantly (p < 0.05) increased DNA damage compared with 
that in cells treated with AcPEI-NPs or not treated with enzymes. The increase 
observed for Fpg was not significantly different from that for Endo III. These results 
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demonstrate that ROS induced by PEI-NPs enhanced the oxidative damage of DNA, 




Figure 4. DNA damage (% tail DNA measured using the comet assay) in HUVEC cells exposed to 
various concentrations (5, 50 and 300 µg/ml) of PEI/NPs or AcPEI/NPs. ETP (etoposide, 0.5 µg/ml) 
and DMSO (dimethyl-sulfoxide 1%) were used as positive and negative control, respectively. The 
results are expressed as the mean ± SD of three separate experiments for each data point of the olive 
tail moment (% DNA in tail × distance between centres of mass). Values are significantly different 
from control: *p < 0.05 compared with PEI/NPs. 
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Figure 5. Oxidative modifications to the DNA bases evoked by nanoparticles. DNA damage in 
HUVEC cells exposed to PEI/NPs or AcPEI/NPs at 300 µg/ml and measured as percentage of DNA in 
the tail in the alkaline comet assay as probed by endonuclease III and formamidopyrimidine-DNA 
glycosylase at 1 µg/ml. The number of cells scored for each treatment was 100. The results are 




Supplementary information (S1) reports the contribute of PEI-NPs in causing sister 
chromatide exchanges and the formation of micronuclei in peripheral limphocytes, 
effect that was not induced after transfection with AcPEI-NPs. 
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Figure S1. Quantitative evaluation of the formation of micronuclei (Mni) and sister chromatide 
exchanges (SCEs), after cell exposure to PEI-NPs and AcPEI-NPs. 
 
Intracellular ROS production 
 
The presence of oxidized DNA base following incubation of cells with NPs and 
literature data showing that nanoparticles may elicit production of reactive 
oxygen/nitrogen species [3][23] prompted us to evaluate the level of intracellular 
ROS following incubation with NPs. 
The potential for our nanoparticles to induce oxidative stress was tested by 
evaluating intracellular ROS using the DCFH-DA assay. ROS generation in HUVEC 
cells following 24 h of exposure to PEI-NPs and AcPEI-NPs at different 
concentrations is shown in Fig. 6. Fluorescence intensity, indicative of oxidative 
stress (OS) in the cells, increase in a dose-dependent manner after treatment with 
PEI-NPs, and assumed values statistically relevant if compared to controls and 
AcPEI-NPs. No increase of ROS production was demonstrated after addition of 
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AcPEI-NPs to cell culture both at low (50 µg/ml) and high (300 µg/ml) nanoparticle 
concentration. The same trend line was obtained testing ROS production in 






Figure 6. Intracellular ROS generation of PEI- and AcPEI-nanoparticles. HUVEC cells were treated 
with different concentrations of nanoparticles for 24 h. The ROS level of the positive control was set 
at 100%. The negative control was high DMEM culture medium, and the positive control was 
hydrogen peroxide. Values are represented as the mean ± the standard error of the mean (n = 6). *p < 
0.05 compared with negative control. 
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Figure S2. Intracellular ROS generation of PEI- and AcPEI-nanoparticles. Peripheral human 
monocytes  cells were treated with different concentrations of nanoparticles for 40 minutes, with 
intervals of 10 minutes. The ROS level of the positive control was set at 100%. The negative control 
was high DMEM culture medium, and the positive control was phorbol-12-myristate-13-acetate 
(PMA). Values are represented as the mean ± the standard error of the mean (n = 6). *p < 0.05 
compared with negative control. 
 
Effects of nanoparticles on cytokine activation in peripheral blood immune cells 
 
Our results suggest that ROS production by PEI-NP and AcPEI- NP treatment should 
be a cell autonomous phenomenon, since we use an in vitro cell system. Others 
demonstrated that nanoparticles may also elicit an inflammatory response that in turn 
contributes to intracellular ROS production [23]. We decided to carry a preliminary 
experiment to evaluate whether the nanoparticles might induce an activation of 
immune-competent cells. To this end the conditioned media of peripheral human 
lymphocytes and monocytes cultured for 24 h in the presence of 300 µg/ml of both 
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PEI-NPs and AcPEI-NPs were analyzed for cytokine secretion. The human cytokine 
array quantification (Figure 7) did not show any inflammatory cytokine production in 
cell cultures exposed to nanoparticles compared to control unstimulated cells. This 
may suggest that, at least in our experimental conditions, the contribution of 
inflammation response on cyto/genotoxicity of NPs is negligible.  
 
 
Figure 7. Effects of nanoparticles on cytokine activation in peripheral blood immune cells. 
Nanoparticles did not induce inflammatory cytokine production in primary human peripheral blood 
cells cultured 24 h. Cytokine production was evaluated by ELISA and data are expressed as 
percentage of activation values obtained from control cells treated with an immunotoxic agent (PMA) 
and are the mean ± SD of 5 separate   experiments. 
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3.5 Discussion and conclusion 
The dramatic increase in the use of nanoparticles (NPs) in medicine has raised 
questions about the potential toxicity of such materials. Unfortunately, not enough is 
known about how the novel properties of NPs correlate with the interactions that may 
take place at the nano/bio interface. 
Recent results show that seemingly small changes in NP chemistry can cause 
significant differences in potency and safety, making thorough characterization 
critical for the use of NPs in medicine. For example, the difference in electrostatic 
potential between the stationary layer of fluid surrounding the nanoparticles and the 
bulk fluid (zeta potential) is an important physicochemical property that has proven 
to be critical in modulating cytotoxicity effects of nanoparticles [23] For instance, it 
is proposed that nanoparticle cytotoxicity could be modulated by controlling the 
electrostatic interaction between nanoparticles and cellular targets [24]. The effect 
that structure has on toxicity becomes even more complex if we consider that 
essential biological functions, such as cellular uptake, can be influenced by the nature 
of the surface coating on nanomaterials that may be purposely introduced (such as 
dextran) [25] or modified by the biological environment through adsorption of 
proteins and other biomolecules [26]. 
Polyethylenimine (PEI) is an efficient non-viral gene delivery vector readily taken up 
by cells through endocytosis and escapes endosomal degradation by the proton-
sponge effect because of its cationic nature [27][28]. However, the major drawback 
of PEI is its high cell toxicity [29]. Several strategies have been previously studied to 
reduce the toxicity of this cationic material, and to some extent, also maintain its 
transfection performance at the same time. These strategies include the use of 
degradable cross-linkages, synthesis of more linear polymers such as linear PEI, 
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grafting PEI polymers with hydrophobic moieties, and incorporating liposomal 
ingredients with cationic polymers to form polysomes [30]. However, an effective 
and convenient strategy to lower PEI general toxicity remains an unmet need. 
Recent studies on PEI have showed that primary and secondary amines increased 
toxicity, while tertiary amines reduced toxicity [29][31]. Since the amino groups on 
the polymeric backbone are responsible for condensing DNA and for the proton-
sponge effect, modifications of the amino groups have been explored to further 
improve PEI tolerability. In this work, we have modified the amino groups in 
polymer backbone by acetylation with acetic anhydride to alter the protonation 
behavior of the polymer. We demonstrated that acetylated PEI-NPs may represent a 
valid alternative to PEI-NPs for drug delivery. Despite having a reduced surface 
charge, acetylated PEI-NPs still forms nanoparticles with a positive zeta potential. 
The positive charge as well as the enhanced lipophilicity facilitates both their 
association with the cell membrane and their uptake, which explains the little 
difference that we demonstrated in the cell uptake of control and acetylated 
copolymers. As expected, the toxicity of the polymers was reduced by the 
modifications as shown in Fig. 3 (A and B).These data fit very well with literature, 
where several modifications of branched PEI led to decreased charge and lower 
toxicity of the polymer [32][ 
While it appears that partial acetylation does not affect nanoparticle uptake, and 
biocompatibility profile, the genotoxicity and ROS production of the two 
nanoparticulates were strongly dependent by the degree of PEI acetylation. 
By definition, genotoxic agents damage DNA, with resulting loss of DNA integrity, 
mutagenesis, and chromosomal aberrations. Nanoparticles as a group are known to 
induce genotoxic effects by a variety of mechanisms (Singh et al., 2009) including 
(1) direct inter-action with DNA; (2) impairment of the cellular transcription and 
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translation machinery; and (3) inducement of DNA point mutations or/and single- or 
double-strand breaks via ROS generation. While the first two mechanisms seem to be 
related with the genotoxicity of quantum dots, due to their ability to enter the nucleus 
and to localize mainly in perinuclear region, DNA damage caused by ROS seems to 
be relevant for the genotoxicity of PEI nanoparticles. An increased ROS production 
results in an oxidative stress when cells fail to compensate for the increased ROS and 
consequently fail to maintain or restore normal physiological redox-regulated 
functions, leading to toxicological outcomes, such as DNA damage and expression of 
inflammatory cytokines. The expression of inflammatory cytokines is determined 
through transcriptional activation of the gene promoters by redox-sensitive mitogen-
activated protein (MAP) kinase and the transcription factor nuclear factor kappa-B 
(NF-KB) signaling cascades (Tier 2). Following this concept, we con- ducted an 
integrated series of cellular screening assays in presence of PEI-NPs or AcPEI-NPs 
to quantify (i) ROS production, (ii) cytokine expression, and (iii) DNA damage. 
Interestingly, our studies evidenced that the intracellular level of ROS generation and 
DNA damage were significantly reduced using AcPEI-NPs in comparison with PEI-
NPs. 
Overall, the substantial reduction in NP-induced cell toxicity and significant decrease 
in genotoxicity can be achieved especially in nanomedicine applications of NPs. This 
will be clinically valuable if the therapeutical application of NPs is intended for 
management of tough-to-treat disease conditions (e.g. cancer) using high dose levels 
or repeated dosing for which low carrier toxicity is essential. 
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4.1 Summary 
Small interfering RNA (siRNA) targeted therapeutics (STT) offers a compelling 
alternative to tradition medications for treatment of genetic diseases by providing a 
means to silence the expression of specific aberrant proteins, through interference at 
the expression level. The perceived advantage of siRNA therapy is its ability to 
target, through synthetic antisense oligonucleotides, any part of the genome. 
Although STT provides a high level of specificity, it is also hindered by poor 
intracellular uptake, limited blood stability, high degradability and non-specific 
immune stimulation. Since serum proteins has been considered as useful vehicles for 
targeting tumors, in this study we investigated the effect of incorporation of human 
serum albumin (HSA) in branched polyethylenimine (bPEI)-siRNA polyplexes in 
their internalization in epithelial and endothelial cells. We observed that introduction 





of HSA preserves the capacity of bPEI to complex with siRNA and protect it against 
extracellular endonucleases, while affording significantly improved internalization 
and silencing efficiency, compared to bPEI-siRNA polyplexes in endothelial and 
metastatic breast cancer epithelial cells.  Furthermore, the uptake of the HSA-bPEI-
siRNA ternary polyplexes occurred primarily through a caveolae-mediated 
endocytosis, thus providing evidence for a clear role for HSA in polyplex 
internalization. These results provide further impetus to explore the role of serum 
proteins in delivery of siRNA.  
 
4.2 Introduction 
Gene therapy is a therapeutic approach that aims to treat otherwise incurable 
diseases, like viral infections, hereditary disorders and cancer by replacing defective 
genes and the function of aberrant proteins, through gene incorporation in plasmids 
or viral vectors for nuclear delivery [1]. Non-viral systems are however widely 
preferred, in order to reduce cellular toxicity, risk of casual gene insertion in the 
genome and mutagenesis. More recently the discovery of endogenous mechanisms 
involved in regulating gene expression, through antisense oligonucleotides, opened a 
new approach of gene therapy, i.e., targeting a specific gene for silencing in cells. 
RNA interference (RNAi) is a mechanism triggered in the cell cytoplasm by 
exogenous small interfering RNA (siRNA) and endogenous microRNA (miRNA), 
causing the blockade of protein translation, by specific mRNA sequence matching 
[1][2]. The design of synthetic siRNA sequences of 21-25 bp, is nowadays employed 
for specific gene knockdown, with increasing number of RNAi-based drugs in 
clinical trials [3][4].  





The delivery of siRNA includes a lot of challenges, regarding in vivo injection and 
intracellular uptake: siRNA sequences are large and negatively charged and do not 
spontaneously cross the cell membrane. Furthermore, high degradability from 
extracellular nucleases, poor bloodstream circulation, renal clearance and difficulties 
to traverse the endothelial barrier to reach a target tissue are the major issues to be 
considered [5][2].  
The condensation of siRNA with linear or branched cationic polymers, with linear or 
branched structure, is widely used as a packaging and delivery strategy, which 
ensures protection from degradation while promoting non-specific endocytosis and 
intracellular escape from endosomes [5][6]. Polycations although commonly used for 
condensation and delivery of siRNA in vivo, show an inverse relationship between 
backbone charge density and toxicity [7].  
The first cationic polymer-siRNA formulation, to enter clinical trial in 2008, was 
based on cyclodextrin based nanoparticles containing siRNA (CALAA-01) with 
incorporation of transferrin (Tf), as a targeting ligand for tumors [4]. Transferrin 
transports iron in the bloodstream and malignant cells up-regulate the expression of 
the Tf-receptor [8].  
Serum proteins have been recently discovered to serve as endogenous targeting 
ligand and for increasing nanoparticles circulation, after injection [3][9]. In Kim et 
al., have reported that apolipoprotein A-I, a component of the high density 
lipoprotein (HDL), can be assembled with liposomes to address siRNA delivery to 
the liver, through specific receptor-mediated internalization in hepatocytes [10]. 
Therefore, identifying other possible endogenous targeting molecules in circulation 
can provide new insights and opportunities in siRNA delivery. Albumin, which is the 
most abundant protein with physiological function of transporting fatty acids, has 
been explored extensively for the delivery of therapeutic molecules. Most notable is 





the enhanced delivery and efficiency of paclitaxel when delivered as an albumin 
conjugated nanoparticle, Abraxane®[9]. Additionally, albumin has been 
demonstrated to accumulate in tumors by the enhanced permeability and retention 
(EPR) effect and a specific trans-endothelial transportation, and is a promising 
candidate as a carrier for anti-cancer drugs [11][12]. Work to date on using albumin 
as a carrier for gene delivery, has focused on the covalent modification of the protein 
to synthesize cationized albumin (CA) which has then been used for the 
complexation of oligonucleotides [13]. 
Encouraged by these findings, in this study, we explored the role of native 
unmodified human serum albumin (HSA) in mediating the delivery of siRNA in 
endothelial and breast cancer metastatic cells. Branched polyethylenimine (bPEI), the 
most routinely of commonly used cationic polymer for nucleic acids delivery, was 
complexed with siRNA and HSA was added subsequently for electrostatic 
incorporation via bPEI [14][15]. HSA-bPEI-siRNA ternary complexes significantly 
improved internalization and silencing efficiency, compared to bPEI-siRNA 
polyplexes. The presence of free albumin interfered with the internalization, clearly 
suggesting an important role of HSA in mediating the increased transfection. The 
HSA participation in the intracellular trafficking was further elucidated by uptake 
mechanism studies.  
 
4.3 Materials and Methods 
Materials 
TurboGFP Stealth RNAi™ siRNA sequence was designed to target TurboGFP 
mRNA, with the on-line program BLOCK-iT™ RNAi Designer 





(http://rnaidesigner.lifetechnologies.com/). TurboGFP Stealth RNAi™ siRNA was 
used for the characterization studies of the complexes and the silencing experiments. 
Sense sequence: GAUAACGAUCUGGAUGGCAGCUUCA, antisense sequence: 
UGAAGCUGCCAUCCAGAUCGUUAUC.  
BLOCK-iT AlexaFluor 555 control siRNA (Invitrogen, Germany) was used for all 
the uptake and mechanism studies. Branched polyethylenimine (MW 25 kDa) and 
Human serum albumin were purchased from Sigma-Aldrich (Germany). 




Human primary pulmonary microvascular endothelial cells (HPMEC) and human 
breast adenocarcinoma cell line (MDA-MB-231) were used for all the siRNA 
transfection studies. MDA-MB-231 cells were provided by the Centre for Biological 
Signalling Studies (BIOSS) and were genotyped and verified at Labor für DNA 
Analytik (Freiburg, Germany), while HPMEC were purchased from  ScienCell 
(Provitro, Germany).  
MDA-MB-231 were grown in Dulbecco’s modified Eagle’s Medium (DMEM) 
(Invitrogen, Germany) supplemented with 10% FBS (Invitrogen, Germany) and 1% 
penicillin/streptomycin/amphotericin B solution (Pan Biotech, Germany) and 
HPMEC were cultured in Endothelial Cell Medium (ECM), supplemented with 5% 
fetal bovine serum (FBS), 1% endothelial cell growth supplement (ECGS) and 1% 
penicillin/streptomycin/amphotericin B solution (ScienCell, US/Provitro, Germany). 
Cells were cultured in a humidified incubator containing 5% CO2 at 37˚C.  
TurboGFP expressing cells were obtained by TurboGFP stable transfection in MDA-
MB-231 and HPMEC, carried by lentiviral transfection of non-silencing control 





pGIPZ vector (Thermo Scientific, Germany). MDA-MB-231 and HPMEC were 
seeded in 6 well-plates at the concentration of 7.0*10
4
cells/well and transfected with 
the lentiviral solution in complete medium for 24 hours. Puromycin (Sigma-Aldrich, 
Germany) was added at the concentration of 4µg/ml after 48 hours, to select the 
successfully transfected population.  
 
Synthesis of the complexes 
 
The ternary complexes were prepared in DNAse-RNAse free water (GIBCO, 
Germany). SiRNA was mixed with branched polyethylenimine25kDa (bPEI) at 
nitrogen/phosphate groups ratio (N/P ratio) of 10 and incubated at room temperature 
for 20 minutes. The reaction was performed with a fixed siRNA concentration of 22 
µg/ml BLOCK-iT Alexa Fluor 555 control siRNA (~13.8 kDa) or 26 µg/ml of 
Stealth RNAi™ TurboGFP siRNA sequence (~16.5 kDa). Human serum albumin 
67KDa (HSA) was added at a final concentrations of 0,125 mg/ml, for further 30 
minutes. bPEI solution and HSA solution were prepared in DNAse-RNAse free 
water and filtered with a 0.22 µm cellulose acetate filter (Corning,NY).  
Lypofectamine2000 (Invitrogen, Germany) was used as a positive control, for the 
silencing experiments. The lipoplexes were prepared with the same siRNA 
concentration used for HSA-bPEI-siRNA ternary complexes and bPEI-siRNA 
polyplexes (26 µg/ml), following the protocol guide from Invitrogen, in relation to 












Gel Retardation assay and RNAse protection assay 
 
RNase protection assay was performed incubating the samples with 17µg/ml of 
RNAse solution (Sigma-Aldrich, Germany) for 30 minutes. Gel retardation assay and 
RNAse protection assay were performed loading 10 µl aliquot of the sample, 
together with 2µl of loading buffer (Invitrogen, Germany) on a 4%  agarose gel, 
prepared in 1X Tris-boric acid-EDTA (TBE) buffer. The Electrophoresis was 
conducted in TBE buffer at 100V for 1 hour. Gel bands were stained with Gel red 
nucleic acid stain (Biotium, US) for 30 minutes and visualized under UV Fusion FX7 
(PeqLab). 100bp and 10bp DNA ladder (Invitrogen, Germany) were run in the gel to 
confirm siRNA integrity. 
Determination of Size and Zeta Potential 
The mean complexes size, polydispersity index value and zeta potential were 
measured by DelsaNano C particle analyzer (Beckman Coulter). The complexes 
were diluted 1:3 with distilled DNAse-RNAse free water. Morphology and size of 
the complexes were furthermore studied by Transmission Electron Microscopy 
(TEM), using Zeiss LEO 912 Omega transmission electron microscope, at an 
accelerating voltage of 120 kV. The prepared samples was settled in CF-400-Cu 
square mesh copper grids (Electron Miscroscopy Sciences, USA) and stained with 2 
% uranil acetate solution. ImageJ software was used to create a statistic of the size of 
the complexes. 
 
Microscopy transfection studies 
 
Cell microscopy studies were performed in 8-well chambers (Sarstedt, Germany). 
1.5*10
4
 cells were seeded 24 hours before the experiment in 300 µl of complete 





medium. Alexa Fluor 555 siRNA-labeled complexes were incubated at 37˚C for two 
hours. The cells were washed 3 times with Phosphate Buffered Saline PBS (GIBCO, 
Germany) and then were fixed in 4% formaldehyde solution and stained with DAPI 
using Vectashield Mounting Medium (Vector Laboratories, Burlingame). Images 
were acquired in multichannel acquisition with Axio Observer Z1 (Zeiss), with 63X 
oil immersion objective. 
 
Fluorescence activating sorter (FACS) transfection studies 
Quantitative siRNA internalization in cells was studied measuring the mean 
fluorescence value for cell, following the uptake of siRNA-labeled complexes in 
MDA-MB-231 and HPMEC. Cells were seeded in 24-well plate at a concentration of 
1.0*10
5 
in complete medium, 24 hours before the experiment. Cells were then 
transfected with the complexes for 4 hours in 500µl of serum free medium. 
Subsequently, cells were washed with PBS and detached with trypsin from each 
well. Complete medium with 10% FBS was used to block trypsin action. The cells 
were centrifuged at 800 rpm 5 minutes and the pellet was resuspended in PBS 2% 
FBS. The fluorescent signal was detected with FACS Gallios (Beckman Coulter) 
with FL2 channel (excitation laser:488 nm; emission filter: 575 nm) and the data 
were analyzed with Flowing software 2 (Perttu Terho).The histograms in Figure 3b 
and Figure 6 were generated using FlowJo software. Statistics were carried using the 
student t-test module in Excel for paired datasets, assuming a two-tailed distribution 
and equal variance between data sets (homoscedastic). A p value of < 0.05 was 
considered statistically significant. 
 
FACS silencing experiments 





Silencing experiments were conducted with MDA-MB-231 and HPMEC expressing 
TurboGFP. Cells were seeded in 24-well plate at a concentration of 1.0*10
5 
in 
complete medium, 24 hours before the experiment. Cells were transfected with the 
complexes for 4 hours in 500µl of serum free medium. The medium was replaced 
with complete medium, containing FBS, for 72 hours. Cells were then washed with 
PBS and detached with trypsin from each well. Complete medium with 10% FBS 
was used to block trypsin action. The cells were centrifuged at 800 rpm 5 minutes 
and the pellet was resuspended in PBS 2% FBS. The fluorescent signal was detected 
with FACS Gallios (Beckman Coulter) with FL1 channel (excitation laser: 488 nm; 
emission filter 525 nm) and the data were analyzed with Flowing software 2 (Perttu 
Terho). Lypofectamine2000 (Invitrogen) was used as a positive control.The 
histograms in Figure 4 were generated using FlowJo software. Statistics were carried 
using the student t-test module in Excel for paired datasets, assuming a two-tailed 
distribution and equal variance between data sets (homoscedastic). A p value 
of < 0.05 was considered statistically significant. 
 
Cell Viability Assay 
 
To test the cytotoxicity of the different formulations, an 3-(4,5-Dimethylthiazol-
2yl)2,5-diphenyl-2H-tetrazoliumbromide (MTT) (Sigma, Germany) assay was 
executed after the incubation with the complexes. Cells were seeded in a 24-well 
plate 24 hours prior to the experiment. The cells were transfected with the complexes 
for 4 hours in serum free medium. Then the serum free medium was replaced with 
complete medium for 72 hours, testing the cell viability at the same time point of the 
knockdown efficiency. Cells were then washed with PBS and 200 μl of a solution of 
MTT (0.25 mg/ml in RPMI without phenol red) was added and incubated for 3 h at 





37°C. The MTT solution was removed, 200 μl of DMSO were added to each well 
and the absorbance at 550 nm was measured using a Synergy HT plate reader 
(BioTek).  
 
Uptake mechanism studies 
Colocalization studies with selective markers of endocytosis were conducted in both 
cell lines. Alexa-Fluor 647 labeled transferrin (50µg/ml) and Cholera toxin b 
(3.5µg/ml) (Invitrogen, Germany) were used as intracellular markers of clathrin-
mediated endocytosis and caveolae-mediated endocytosis. Alexa-Fluor 555 siRNA-
labeled complexes were transfected for 2 hours in cells and transferrin (Tf) or cholera 
toxin b (CTB) were subsequently added for 30 minutes. Inhibition studies were 
performed with specific inhibitors: Chlorpromazine (2µg/ml for MDA-MB-231 and 
5µg/ml for HPMEC), Filipin III (5µg/ml) and Nystatin (20µg/ml). All the inhibitors 
were purchased from Sigma-Aldrich. Cells were pre-treated for 20 minutes with each 
inhibitor, in serum free medium, and then incubated with the siRNA-labeled 
complexes for 2 hours, without removing the inhibitors. Cells were then trypsinized 
and collected for FACS fluorescence detection. The chosen concentrations of each 
inhibitor were previously tested for cell viability with MTT test (S3).  
 
4.4 Results and discussion 
Characterization of HSA-bPEI-siRNA ternary complex. 
Due to the negatively charged backbone, delivery of siRNA to cells requires it to be 
packaged as a complex with a polycation. Typically, PEI (linear or branched) is the 





polycation of choice. This complexation is important to ensure the stability of the 
siRNA through RNAses and to promote the entry of siRNA into cells. The ternary 
complexes were formed using branched polyethylenimine (bPEI) and HSA was 
introduced as an aqueous solution at pH 7, where it is negatively charged, thereby 
capable of interacting with the positive charged amino groups of PEI (Figure 1a). 
The introduction of HSA to bPEI-siRNA complex induced only modest changes in 
zeta (-potential. However, the size of the complexes dramatically increased. This 
was also confirmed by TEM (Figure 1b, Table1). This increase in size could be due 
to either aggregation of smaller polyplexes or reorganization of the PEI-siRNA 
complexes, in presence of albumin, to a more thermodynamically stable structure.We 
first ascertained if the addition of albumin would impact the capacity of siRNA to 
complex with bPEI. Gel Retardation assay showed total siRNA incorporation by the 
complexes (Figure 1c) and the ability to protect the siRNA against extracellular 
endonucleases was verified by RNAse Protection assay (Figure 1d). HSA adsorption 
on nanocomplexes surface did not alter the ability of siRNA condensation and 
RNAse cleavage protection, which are characteristic of the bPEI-siRNA system [16]. 
 
 
















Figure1. Characterization of HSA-bPEI-siRNA complexes. A) Schematic representation of the two 
steps formulation protocol, where bPEI-siRNA native interaction was preserved and HSA was used 
for interacting with the positive charged amino-groups of bPEI. B) Transmission electron microscopy 
(TEM) images showing the increase in size upon addition of HSA. C) Gel retardation assay, 
demonstrating siRNA complexation on the top of the gel. From left, 10 base pair ladder (L10); free 
siRNA (-); PEI-siRNA (PEI); HSA-PEI-siRNA (+HSA); 100 base pair ladder (L100). D) RNAse 
protection assay, indicating efficent siRNA protection from RNAse degradation. Complexes are 
unaltered on the top of the gel, while free RNA is completely degraded. From left, 10 base pair ladder 
(L10); free siRNA (-); samples incubated with RNAse: free  siRNA (+), PEI-siRNA (PEI) and  HSA-














HSA colocalizes with siRNA in cells and increases transfection efficiency. 
 
To investigate the cell uptake efficiency of the developed system and to understand 
the role of HSA in mediating siRNA delivery, we performed the transfection studies 
in metastatic human breast cancer cells (MDA-MB-231) and human pulmonary 
microvascular endothelial cells (HPMEC). 
These cells were chosen as vasculature is important for tumor survival and lung is 
the prominent organ for epithelial tumor metastasis [17][18]. Additionally, 
endothelial cells and metastatic breast cancer cells have been shown to actively take 
up albumin [19][20]. 
To ascertain the role of HSA in the internalization of siRNA, a colocalization study 
was undertaken, in MDA-MB-231, with fluorescently labeled siRNA. Fluorescence 
microscopy revealed that HSA colocalizes with siRNA, therefore, clearly shown that 
HSA participates in the transcellular uptake of siRNA complexes and their 
trafficking in the cytosol (Figure2). 






Figure 2. Colocalization of HSA and bPEI-siRNA polyplexes in MDA-MB-231 cells. Fluorescence 
microscopy revealed that Alexa-fluor 488 labeled HSA and Alexa-fluor 555 siRNA access in the same 
intracellular trafficking. (DAPI nuclear stain, blue; Alexa-fluor 555 siRNA labeled complexes, red; 
Alexa-fluor 488 labeled HSA, green). White arrows indicate points of colocalization. Scale bar: 
20µm. 
 
The quantification of HSA-bPEI-siRNA complex internalization was first evaluated 
in MDA-MB-231 and HPMEC and compared with bPEI-siRNA polyplexes, using 
flow cytometry (FACS). Alexa dye labeled siRNA formulations were used for the 
study. To eliminate the interference from the transfection medium, uptake studies 
were conducted in serum free medium. Fluorescence micrographs of transfected cells 
are shown (Figure 3a). FACS analysis showed that the ternary complexes were taken 
up to a significantly greater extent in comparison to bPEI-siRNA polyplexes. The 
uptake efficiency was about 11 fold greater, in MDA-MB-231, and about 6 fold 
greater, in HPMEC, over bPEI-siRNA control. In contrast to HPMEC, where a single 
gaussian distribution was observed, in MDA-MB-231 cancer cells a bimodal 
distribution was observed, with about 55% of the population showing higher 
internalization and the remaining population having similar uptake efficiency of 
bPEI-siRNA (Figure 3b). 


















Figure 3. Uptake of HSA-bPEI-siRNA and PEI-siRNA complexes in MDA-MB-231 cells and 
HPMECs. A) Representative fluorescence micrographs showing siRNA labeled complexes in cells 
(DAPI nuclear stain, blue; Alexa-fluor 555 siRNA labeled complexes, red) Scale bar: 20µm. B) FACS 
quantitative measurements, expressed as mean fluorescence value for cell,reveald increased uptake by 
HSA-bPEI-siRNA complexes, compared to bPEI-siRNA control, in both cell lines. Results are shown 
as mean ± SD (n=3). MDA-MB-231 cells ** p<0.001,  HPMECs **p<0.005. 
 





Ogris et al., have reported that the conjugation of PEI with tranferrin (Tf) could 
enhance gene delivery to tumors. Despite the formation of complexes up to 
micrometer size, they observed increased cell uptake and gene expression [21]. In 
this study, the large HSA-bPEI-siRNA complexes also showed higher uptake. It is 
possible that a loose association of smaller polyplexes occur and this could be the 
reason of the higher efficiency. Further evidence in support of the role of HSA, in 
transporting or facilitating siRNA internalization, was obtained by carrying out 
transfection in presence of serum, where albumin is the most dominant protein. 
Interestingly, the transfection efficiency of the ternary complex was diminished (S1). 
This could be due to competition between free albumin and albumin associated with 




Figure S1. Uptake study comparing HSA-bPEI-siRNA uptake in transfection medium with and 
without fetal bovine serum (FBS). 
 





HSA increases gene silencing in MDA-MB-231 and HPMEC 
To see if the increased uptake efficiency translates into higher availability of free 
siRNA, a gene silencing study was undertaken using cell lines expressing TurboGFP. 
In accordance with the higher internalization, HSA-bPEI-siRNA showed about 12 
and 53 times more silencing than bPEI-siRNA, in MDA-MB-231 and HPMEC, 
respectively, and was comparable with Lipofectamine, as seen by the reduced 
TurboGFP fluorescence in cells transfected with the ternary complex. Similar results 
were also obtained in HPMEC, indicating that HSA complexation with bPEI-siRNA 
presents a general strategy for improving the efficiency in siRNA delivery. The lack 
of any appreciable gene silencing using  bPEI-siRNA may be attributed to poor 
siRNA internalization. In MDA-MB-231, 62 ± 1.4% of the cell population was 
efficiently silenced with HSA-bPEI-siRNA complexes, with cell fluorescence 
reduction of 81 ± 2.4% (Figure 4a). For HPMEC, 69 ± 2.0% of cells showed efficient 
knockdown, having fluorescence reduction of 88 ± 3.3% for HSA-bPEI-siRNA 
(Figure 4b). Lipofectamine2000-siRNA showed similar results, in terms of  
effectively silenced population and knockdown efficency. The contribution of 
differences in cell viability, in the observed higher transfection efficiency with the 
ternary system, can be eliminated, as cells exposed to HSA-bPEI-siRNA and bPEI-
siRNA complexes showed comparable viability in MTT assay (S2). 
 
 








Figure 4. Protein knockdown efficiency in cells expressing TurboGFP. Cell fluorescence reduction 
was estimated to evaluate the percentage of TurboGFP silencing. Both cell lines showed improved 
siRNA efficiency compared to bPEI-siRNA control. A) MDA-MB-231 cells ***p<0.0005. B) 
HPMECs***p<0.0005. The silencing efficiency resulted comparable with Lipofectamine2000-siRNA 
lipoplexes (LFA-siRNA). Results are shown as mean ± SD (n=6). 
 






Figure S2. MTT test showing cell viability after transfection. 
 
Uptake Mechanism of HSA-bPEI-siRNA complexes 
In order to understand which uptake mechanism mediates the higher siRNA delivery 
efficiency of HSA-bPEI-siRNA, the involvement of clathrin-mediated endocytosis 
and caveolae-mediated endocytosis was elucidated. The size of the complexes 
influences their entry in cells and their intracellular trafficking. Previous studies have 
demonstrated that nanospheres with diameter lower than 200 nm were preferentially 
internalized by chlatrin mediated pathway, while particles higher than 500 nm 
followed the activation of caveolae or ―caveosomes‖, derived from multiple caveolae 
assemblies on the cellular surface [22][23].  
We investigated the uptake inhibition of siRNA-labeled complexes in presence of 
Chlorpromazine (CPZ), a known inhibitor of the clathrin pathway, and Nystatin 





(Nyst) and Filipin III (Fil III), both cholesterol depletors, that block the formation of 
caveolae.The inhibitors concentrations were chosen so as to have minimal impact on 




Figure S3. MTT test showing cell viability after incubation with inhibitors, at the concentrations used. 
 
We observed that the ternary complexes are primarily taken up by the caveolae 
uptake mechanism in both cells, which this uptake pathway was more pronunced in 
MDA-MB-231. The uptake through clathrin mediated endocytosis was around 30% 
in MDA-MB-231 and HPMEC (Figure 5a, 5b). Colocalization with cholera toxin b 
(CTB) in fluorescence microscopy further confirmed the intracellular trafficking 
through caveolae (Figure 5c, 5d).  
 















Figure 5. Uptake mechanism study of HSA-bPEI-siRNA complexes in MDA-MB-231 cells and 
HPMECs. The uptake inhibition was quantified in presence of Nystatin (Nyst), Filipin III (Fil III) and 
Chlorpromazine (CPZ). Fluorescence reduction was evaluated in FACS. A) Inhibition in MDA-MB-
231cells; B) Inhibition in HPMECs. Results are shown as mean ± SD (n=3). From the study, partial 
involvement of clathrin-mediated pathway was observed, with around 30% inhibition by CPZ, and 
low colocalization with Tf. Predominant activation of caveolae-mediated endocytosis resulted in the 
internalization of HSA-bPEI-siRNA complexes, in both cell lines. Colocalization study in 
fluorescence microscopy with uptake markers cholera toxin b (CTB), marker of caveolae-mediated 
pathway, and transferrin (Tf), marker of clathrin-mediated pathway, is shown in C) MDA-MB-231 
cells; D) Colocalization results in HPMEC. White arrows indicate points of colocalization. Scale bar: 
20µm. 
 
It is well known that endothelial cells have high expression of caveolae [24]. Also 
multidrug resistant (MDR) cancer cells have been shown to significantly overexpress 
caveolae [25]. Since we have shown that the particles appear to be uptaken through 
caveolae mediated endocytosis, the higher efficiency could maybe due to the fact that 
this pathway is able to bypass lysosomal degradation [26][22]. 
Gp60, a protein that is associated with caveolae complexes has been shown to aid in 
the transport of albumin across endothelial and epithelial barriers [27][20]. 





Therefore, the specific role of gp60 in enhancing the uptake efficiency of the ternary 
complex needs to be investigated further. 
To further elaborate the role of albumin in the uptake of HSA-bPEI-siRNA 
complexes, we substituted HSA with bovine serum albumin (BSA) and we made an 
interesting observation, that the uptake efficiency was diminished by over 2 fold in 
both cell lines. Although HSA and BSA yielded complexes comparable in size, they 
showed different uptake profiles (Figure 6) and this clearly shows that human 
albumin confers specificity in the uptake in human cells. Similarly, it has been 
postulated that the higher efficiency observed when paclitaxel is covalently linked to 
















Figure 6. Uptake efficiency comparing complexes formed with BSA and HSA. Uptake efficiency was 
evaluated by FACS. (A) Study in MDA-MB-231 cells, **p<0.005; B) Study in HPMECs, *p<0.01. 
Results are shown as mean ± SD (n=3). Complexes formed with BSA showed reduced internalization 
compared with HSA, confirming the role of HSA in improving siRNA delivery in both cell lines. 
 
 






In this study, we evaluated the role of native HSA in mediating the uptake and 
silencing of siRNA, towards cells expressing TurboGFP. It was observed that the 
presence of albumin on the exterior of the bPEI-siRNA polyplexes dramatically 
improve uptake and gene silencing in both human endothelial and tumor epithelial 
cells. Inhibition studies suggest a role for caveolae mediated endocytosis in the 
uptake of the ternary complexes. This is extremelly promising for the delivery of 
siRNA for in vitro studies. 
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5.1 Summary 
Polyethylenimine (PEI) is a synthetic cationic polymer that resulted particularly 
efficient in condensing nucleic acids and in mediating their intracellular uptake [1]. 
The high density of amino groups allows the formation of nano-scale polyplexes 
with nucleic acids and electrostatic interactions with the cellular membrane, but the 
major limitation of PEI applicability in vivo is the cytotoxicity, associated with the 
high positive charge [2][3]. In our previous work we presented the possibility to 
reduce PEI toxicity by partial acetylation of primary amino groups in PEI backbone, 
creating a  more suitable delivery agent for in vivo application. In particular, the 
acetylation of 50% of the amino groups of PEI (AcPEI), forming AcPEI based 
nanoparticles by co-polymerization with PLGA (AcPEI-NPs), did not affect the 
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uptake and gene delivery efficiency of nanoparticles in endothelial cells, but reduced 
the genotoxic and immunotoxic effect, observed with PEI-NPs [4]. In this work, we 
considered the application of AcPEI-NPs in bone regeneration and we investigated 
their uptake efficiency in human primary osteoblasts (hOB) and the impact on 
cellular differentiation and mineralization, for future utilization in the delivery of 
genes or small interference RNA (siRNA). We obtained that AcPEI-NPs are 
internalized by hOB similarly to non-acetylated PEI-NPs, in a concentration and time 
dependent manner. Furthermore, AcPEI-NPs resulted to not activate cell death, 
neither by necrosis or apoptosis process. Investigating the effect of NPs on osteoblast 
activity, we observed that AcPEI-NP, free of the delivery agent, significantly 
increase alkaline phosphatase (ALP) activity, compared to PEI-NPs and non-
transfected hOB. Extensive study on the expression of late differentiation marker and 
mineralization activation, did not confirm osteogenesis that can be improved with 
nucleic acids delivery for gene therapy. 
 
5.2 Introduction 
Over the last decade, gene therapy has captured the scientific interest with the 
purpose to modify gene expression, delivering foreign genes or inhibiting the 
expression of aberrant proteins expression, for treating hereditary disorders [5]. The 
challenge of applying genetic medicine in tissue engineering consists in the 
possibility to regenerate diseased organs or tissues, by the use of genetically 
corrected undifferentiated cells, in order to direct the regeneration versus normal 
tissues [6]. Somatic stem cells conserve the capacity of self-renewal and 
differentiation in cell types of the tissue of origin, under appropriate stimuli. 
Therefore, the sophisticate development of non-viral gene delivery vectors has been 
Chapter 5: Biocompatible cationic nanoparticles for gene delivery in bone tissue engineering: uptake 




accompanied with the possibility to transplant genetically modified cells expanded in 
vitro, or, alternatively, to immobilize growth factors genes in a scaffold matrix, with 
the aim of acting on local multipotent cells. Tissue regeneration is strictly regulated 
by the action of growth factors and cytokines and, nowadays, the delivery of 
signalling molecules has been overcome by a more effective growth factors gene 
delivery, which counteract the short half-life of signalling proteins and the overall 
cost needed for reaching a biological effect [7].  Short interfering RNA (siRNA) has 
been also delivered to cells for activating or down-regulating specific downstream 
pathways [8].  
Nanotechnology has enabled, so far, the development of lipid and polymer-based 
nanoscale devices that, conjugated with nucleic acids, can act as "Trojan horse" 
vectors, directed to a specific tissue at a distant site from the injection [9]. Pre-
requisite for injectable devices is nanoparticles stability, effective genetic material 
condensation, good cellular uptake, tolerance from the immune system and absence 
of cytotoxicity. In our previous work, we developed acetylated PEI-NPs (AcPEI-
NPs), a compelling alternative strategy to PEI-NPs for major biocompatibility and 
similar transfection efficiency [4]. In this work, we considered the application of 
AcPEI-NPs in bone regeneration and we investigated their internalization efficiency 
in human primary osteoblasts and the impact on cellular differentiation and 
mineralization, for future therapeutic utilization. Cell therapy is a promising 
alternative to bone autografts, to afford every year more than 500,000 surgical 
interventions for bone fractures, and bone injuries of surgical, degenerative or 
traumatic causes [7]. A recent study has developed cationic PEI-pDNA (encoding 
PDGF-B) complexes, incorporated in a collagen scaffold, to induce osteogenesis. 
The expression of PDGF-B in bone marrow stromal cells significantly improve cell 
proliferation and new bone formation [10]. With the purpose of increasing the safety 
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of PEI delivery system for bone regeneration, we studied AcPEI-NPs internalization 
in hOB and the effects on cell viability and activity. From our results, we observed 
that PEI acetylation did not alter the uptake efficiency of NPs, as demonstrated in 
comparison with PEI-NPs. Deep studies in the uptake mechanism, showed an 
activation of endocytosis, by non specific clathrin and caveolae mediated pathways 
and colocalization studies demonstrated the incorporation in endosomes, without 
final accumulation in lysosomes. This results, together with the absence of 
cytotoxicity post-transfection, render AcPEI-NPs a promising candidate for gene 
therapy in bone regeneration. Furthermore, investigations on hOB activity, after 
transfection with NPs, have suggested a role of PEI acetylation in promoting the 
early stage of osteoblast differentiation, inducing increased alkaline phosphatase 
(ALP) activity. Future studies will be focused on the  incorporation of therapeutic 
plasmid genes or small interference RNA (siRNA) for  improving bone osteogenesis. 
 
5.3 Materials and methods 
Materials 
Branched PEI (MW, 25 kDa) and poly(vinyl-alcohol) (PVA) were obtained from 
Sigma Aldrich (Milan, Italy). D,L-Lactide/Glycolide copolymer (PLGA, 
PURASORB®, inherent viscosity 0.20 dl/g) was a generous gift from PURAC 
(Gorinchem, The Netherlands). Details of the synthesis of the PEI-PLGA copolymer, 
as well its physicochemical properties were previously described [4]. Briefly, 
copolymer of branched PEI (PEI) or acetylated PEI (AcPEI) with PLGA were 
prepared using a two-step procedure. First, PLGA was activated by DCC  and NHS 
and, afterwards, the copolymerization was conducted at a PLGA:PEI molar ratio of 
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Acetylated PEI (AcPEI) was obtained as described by N.P. Gabrielson and D.W. 
Pack, 2006 [11]. To determine the extent of acetylation, each polymer was dissolved 
in D2O and 
1
H NMR spectra were acquired on a Varian Unity 400 with a 5-mm 
probe. The extent of primary and secondary amine acetylation was determined by 
peak integration, using the formula reported by Nathan P. Gabrielson and Daniel W. 
Pack [11]. Nanoparticles based on PLGA-PEI and AcPEI-PLGA copolymerization 
were prepared directly from the reaction solution by a simple emulsion procedure. 
The reaction was stopped after 3 h by ice cooling, and 2 mL of chloroform solution 
were homogenized with 20 mL of 0.5% PVA aqueous solution by means of an 
ultrasonic processor. The nanoparticles suspension was stirred at 200 rpm rate for 24 
h for chloroform evaporation. The obtained nanospheres were collected by 
centrifugation in a high speed centrifuge at 16000 rpm for 15 min, carefully washed 
to remove unreacted PEI with a water/methanol mixture, and then freeze dried. 
Nanoparticles were stored at 4°C and characterized as previously described [4]. 
Fluorescent nanoparticles were obtained dissolving 6 mg of Coumarin 6 in aqueous 
solution, finally added to polymer solution before homogenization. 
Before incubation with cells, the nanoparticles were suspended in culture media 
containing 2% penicillin-streptomycin at a concentration of 10 mg/ml, subjected to 
sonication in ice for 20 minutes at maximum setting in continuous mode (Branson 
Sonifier), and sterilized by filtration using 0.45 m gauge filters (Sartorius Stedim 
Biotech GmbH, Goettingen, Germany). Nanoparticles eventually entrapped in the 
filter have been recovered by washing the filter with an equal volume of media, 
obtaining a final solution of nanoparticles of 5 mg/ml that has been used as stock 
solution for all in vitro tests.  
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Primary osteoblasts were grown from explants of human trabecular bone fragments 
from knee joints, isolated during surgery interventions (kindly provided by the 
Orthopedic Institute, Major Caritas Hospital, Novara, Italy). The osteoblasts (hOB) 
were cultured in Iscove’s modified Dulbecco’s medium supplemented with 10% fetal 
calf serum (Hyclone, USA), 2 mM L-glutamine, and antibiotics for 2–3 weeks. Cells 
cultured from up of three passages were used for all experiments.   
Cellular uptake  
After 24 hours of adhesion, cells were incubated for 1 hour with fluorescent labeled 
nanoparticles at different concentrations, ranging from 10 to 300 µg/ml, in order to 
study the kinetic of uptake. Besides, at fixed concentration of nanoparticles (300 
µg/ml) time dependent uptake was tested, over a time course ranging from 5 min to 1 
hour (37°C, 5% CO2). After nanoparticles incubation, the cells were washed and 
detached by trypsinization, centrifuged and resuspended in a 0.4% trypan blue (TB) 
solution in PBS, to quench the extracellular Coumarin 6 fluorescence [12]. This 
assay is based on the observation that TB dye, quenching the Coumarin fluorescence 
of a extracellular particles causes red fluoresce, whereas internalized particles will 
release green fluorescence. Cells were then centrifuged, the TB solution was 
removed, the cell pellet was resuspended in PBS, and each sample was analyzed on a 
laser scanning cytometer FACS Calibur (Beckton Dickinson, NJ, USA), for green 
and red fluorescence. 10,000 cells were measured in each sample. Furthermore, time-
lapse fluorescent microscopy was conducted to confirm the internalization time. 
Fluorescent and Phase images of viable cells were acquired with Leica DM 2500 
microscope system from Leica (Leica Microsystem, Milano, Italy) that included an 
aqueous immersion objective 63x and an incubation enclosure around on the 
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microscope stage. This system maintained normal cell culture conditions (37°C, 5% 
CO2 atmosphere, 100% relative humidity) and acquired images on a specific region 
regularly (every 5 min in this study). Human osteoblasts were incubated with the 
studied nanoparticles at a concentration of 300 g/ml, throughout 1 hour of 
experiment. The fluorescence was detected through a BP 515-560 nm excitation 
filter and images have been acquired using a Leica Q550FW camera and analyzed 
using Qwin Image Analysis software (Leica, Heidelberg, Germany). Fluorescence 
images were processed digitally for background fluorescence correction from 
nanoparticles that remained suspended in the media solutions. Uneven fluorescence 
excitation was corrected by normalizing all images by a flat field image that was 
generated by imaging a spatially homogeneous glass filter of 475 nm. Correction for 
background fluorescence was a simple background intensity subtraction, where the 
fluorescence intensity attributed to background was determined from cell-free areas 
(as determined by phase contrast images) within each region of interest. The 
background fluorescence varied during the different experiments, so the background 
fluorescence intensity was determined at each point. The total intensity over the 
whole image was then summed to yield a measurement of the relative accumulation 
of nanoparticles by cells within the region of interest. 
 
Inhibition studies  
 
To explore different mechanisms of nanoparticles interaction with human osteoblasts 
and trafficking across the plasma membrane, uptake of PEI-NPs and Ac-PEI-NPs 
was studied under different blocking conditions (Table 1).  
Table 1. Inhibitors and concentrations used for uptake mechanism studies. 
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In all cases, cells were incubated with the different inhibitors for 30 min before the 
addition of the NPs, and then co-incubated with the NPs for 1 h. Untreated cells were 
used as negative control and cells incubated with NPs at 37°C, without the 
incubation with inhibitors, as positive control. The fluorescence associated with the 
Coumarin-NPs inside the cells was measured in a SpectraMAX®M5 multidetection 
microplate reader at an excitation wavelength of 480 nm and an emission wavelength 
of 529 nm. Results were expressed as relative fluorescence units (RFU). Each assay 
was performed five times in triplicate. 
Intracellular localization of nanoparticles 
After 1 hour of time lapse microscopy, cells were fixed for 30 min with 4% 
formaldehyde solution in PBS at room temperature, then washed with PBS and 
stained with the antibodies for RAB5 and LAMP1, to evidence endosomal and/or 
lysosomal colocalization. Briefly, cells were incubated ON at 4°C with primary 
antibodies: LAMP1 (20 g/ml) and RAB5 (2 g/ml) (Abcam, Cambridge, UK); after 
PBS washings cells were incubated 1 hour at room temperature with, respectively the 
Texas Red anti-mouse (Vector Lab, CA USA) secondary antibody used at 3g/ml 
and the IRIS 5-goat anti-mouse (Cyanine Tecnologies, Torino, Italy) secondary 
antibody used at 2g/ml. Dried cells were mounted with an anti-photobleaching 
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medium (Vector) and observed at confocal microscopy (Leica DM IRE2) at 40x 
magnification. Images have been acquired after excitation with Argon laser at 488 
nm, a Helium-Neon-Green laser excitation at 543 nm and a Helium-Neon-Red laser 
excitation at 633 nm. Coumarin 6 labeled nanoparticles were shown as green spots at 
510 nm emission;  Texas RED positive RAB at 620 nm emission and IRIS positive 
LAMP at 680 nm emission. Images were recorded separately in each fluorescence 
channel and merged afterwards. 
Cytotoxicity tests 
Necrosis was evaluated through the quantification of the activity of lactate 
dehydrogenase (LDH) in culture media of cells cultured 6 hours, 1 day, 3 and 5 days 
with samples at a final concentration of 300 g/ml using a detection kit from Roche 
(Roche Applied Science, Basel, Switzerland). Released LDH catalyzed the oxidation 
of lactate to pyruvate with simultaneous reduction of NAD+ to NADH. The rate of 
NAD+ reduction was directly proportional to LDH activity in the cell medium and 
was measured as an increase in absorbance at 340 nm. The activity of the LDH 
enzyme rises when cells are damaged: the LDH activity induced by samples was 
compared to the effect induced by a toxic agent Triton X100 0.05% in phosphate-
buffer saline (PBS) and to non stimulated negative control (CTR-). 5 replicates for 
each studied concentration were prepared for in vitro tests. 
Apoptosis has been studied by Western Blot. After exposure to nanoparticles (PEI-
NPs and AcPEI-NPs) at 5, 50, and 300 μg/ml for 24 h, cells were lysed in hot buffer 
(50% H2O, 25% SDS10%, 25% Tris-HCl pH 6.8), and 20 g of total proteins in 
sample buffer (5% mercaptoethanol, 0.5% bromophenol blue) were used for SDS-
PAGE. Blotted proteins were blocked with 5% free fat dried milk in PBS pH 7.4, for 
1 h at room temperature, and incubated overnight with primary antibodies (Bax, Bcl-
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2, tubulin and caspase 9, from Calbiochem, Darmstadt, Germany) at a ratio of 1:500 
in PBS. After washing 3 times with PBS solution with Tween 20 0.1%, membranes 
were incubated with secondary anti-mouse or anti-rabbit antibody conjugated with 
peroxidase (PerkinElmer, Shelton, CT-USA) for 1 h at room temperature. Protein 
bands were visualized using enhanced chemiluminescence substrate (PerkinElmer) 
detection reagents in a chemisensitive visualizer (VersaDoc, BioRad, Italy). Tests 
were performed in triplicate for each experimental condition. 
Alkaline phosphatase activity 
Alkaline phosphatase activity (APA), was determined by an assay based on the 
hydrolysis of p-nitrophenylphosphate to p-nitrophenol. hOB seeded in 24-well 
culture dishes at 2x10
4
 cells/well were collected after treatment with three different 
concentrations of nanoparticles (5, 50 and 300 g/ml), rinsed three times with PBS 
and lysed with 60 l of a hot solution composed by 75% H2O, 2.5% SDS10%, 25% 
Tris-HCl pH 6.8. To 50 l of this solution, 50 l of substrate (1mM 
paranitrophenyl-phosphate in 1 M diethanolamine + 1 mM MgCl2 pH 9.8 all from 
Sigma) were added. The mixture was incubated 30 min at 37°C and measured on a 
Bio-Rad micro-plate photo-spectrometer reader at 405 nm (Bio-Rad, Milan, Italy) 
and results (n=3) expressed in M p-nitrophenol. Results were normalized per 
microgram of cell protein. Protein content was measured in cell lysate by 
Bicinchoninic Acid (BCA) protein assay reagent kit (Pierce Biotechnology, 
Rockford, IL, USA). 
 
Collagen estimation 
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hOB collagen synthesis was quantified by a picrosirius dye staining. Cells were 
previously observed in light microscopy for detecting the presence of collagen, 
afterwards the samples were eluted with 0.1N NaOH and the absorbance quantified 
at  = 540 nm in a Model 450 microplate reader (Bio–Rad). The collagen 
concentration  of each sample was calculated from the ratio between the absorbance 
of the samples and a standard curve of collagen at known concentrations. The curve 
was obtained as follows: calf skin type I collagen (Sigma) was dissolved overnight in 
0.2% acetic acid (Sigma) at a concentration of 1 mg/ml. The solution was then 
diluted from 4 to 0.5 g/50 L to obtain a standard curve. The 50 µl of collagen 
standard were plated into a microtiter plate and incubated at 37°C for 16 h 
(humidified) and then 24 h at 37°C (dry). Wells were washed three times with 200 
L of distilled water, filled with 100 L of 0.1% Sirius Red F3BA (BDH, Milano, 
Italy) in saturated picric acid (Sigma) (w/v) and stained for 1 h at room temperature. 
The plates were washed five times with 200 L of 10 mM HCl for 10 s per wash and 
the collagen bound stain was eluted with 200 L of 0.1M NaOH for 5 min, and read 
at  = 540 nm in a Model 450 microplate reader (Bio–Rad). Data were reported as 




For mineralization assay, cells were seeded at 2 x 10
4
 cells/well in 24-well culture 
plates. Cells were cultured in growth medium for l day and then the medium was 
changed  to calcification medium, containing 10 mM -glycerophosphate (Sigma) 
and 50 g/ml L-ascorbic acid (Sigma). Samples were treated with nanoparticles at 
the concentration of 50, 100 and 300 g/ml. The medium supplemented of 
nanoparticles was replaced twice a week. As negative control we have used cells 
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cultured in calcification medium, and as positive control cells cultured in 
calcification medium stimulated with 10 mM dexamethasone (DEX). On day 24, 
hOB monolayers were tested for mineralization by calcein staining. Cells were 
treated overnight at 5% CO2/95% air at 37°C with culture medium containing 5 
g/ml calcein, then cells were washed 2 times with PBS and examined 
microscopically using a BP 515-560 excitation filter. Measurement of mineralized 
nodules formed in culture was determined by acquiring 8 random calcein 
fluorescence images in fields of 1.0912 m
2
 in each experiment, which has been 
repeated 4 times (n=32). Images have been acquired using a Leica Q550FW camera 
and analyzed using Qwin Image Analysis software (Leica, Heidelberg, Germany). 
Osteogenic marker expression by Real Time PCR 
Cells were plated at a density of 1x10
5
 cells/well in 6 multiwell plates and cultured 
for 7 and 21 days with nanoparticles used at 300 g/ml. Total RNA was isolated 
using a commercial kit, RNeasy mini kit (Qiagen, Hilden, Germany), according to 
the manufacturer’s instructions. Total RNA was quantified using Nanodrop 2000c 
spectrophotometer (Thermo Scientific, Wilmington, USA), and 200 ng of total RNA 
were reverse transcribed (RT) using High-Capacity cDNA Archive Kit in a final 
volume of 40 l (Applied Biosystems, Foster City, CA, USA), as described by the 
manufacturer. The RT thermal cicle was 25°C for 10 min, 37°C for 120 min, 85°C 
for 5 min and kept at 4°C. 
Real-time RT-PCR is considered the gold standard for mRNA quantitative 
evaluation. mRNA levels were measured by real-time RT-PCR based on TaqMan 
methodology, using CFX96 Real-Time System C 1000 Thermal Cycler (BioRad, 
Milano, Italia). Real-time data analysis was performed with BioRad CFX Manager 
2.1 software. A reference gene was identified for GADPH stable expression. Primers 
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and probe for osteopontin (OPN), osteocalcin (OCN) and receptor activator of NF-
kB ligand (RANKL) mRNA were provided by TaqMan gene expression assay 
(Applied Biosystems). 
Amplification reactions were performed with SSOFast Probes Supermix with ROX 
(BioRad), using 5 l of cDNA in a final volume of 20 l. Primers and probes were 
added to the reaction mixture according to the manufacturer’s directions. All 
reactions were performed in duplicate. Conditions for quantitative real-time PCR 
were: 2 min denaturing step at 95°C and then 40 cycles of 15 s at 95°C and 1 min at 
60°C. Primer specific cloned PCR-products served as positive controls for the PCR, 
while water was used as negative control. Every set of experiments was carried out 
with cDNA of the same sample to exactly compare the expression of the different 
genes of interest. Target gene expression was normalized to GADPH mRNA 
expression. Relative differential gene expression was calculated according to [13]. 
 
Statistical Analysis 
Statistical analysis of data was carried out using the SPSS for Windows software. 
Multiple comparison of data was performed using one-way analysis of variance 
(ANOVA), Bonferroni t-test was applied to evaluate differences in the trend of the 
measured parameters. p value was obtained from the ANOVA table and the 
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Cell uptake, trafficking and intracellular localization of AcPEI-NPs in hOB 
AcPEI-NPs were firstly tested for internalization efficiency in human primary 
osteoblasts (hOB). We investigated the cellular uptake in presence of either AcPEI-
NPs and PEI-NPs and we observed that the uptake efficiency was not altered by the 
acetylation of PEI, as shown in confocal micrographs (Figures 1A and 1B). Although 
the reduction in zeta-potential, compared with PEI-NPs [4], AcPEI-NPs retained a 
net positive charge that ensured good transfection efficiency in hOB. The kinetic of 
hOB internalization with Coumarin-6 loaded nanoparticles, resulted, quantification, 
concentration and time dependent by flow cytometry (FACS) quantification. We 
tested 5 different PEI-NPs and AcPEI-NPs concentrations (10g/ml, 25g/ml, 
50g/ml, 100g/ml, 300g/ml), showing that the increased uptake was directly 
proportional to the increased concentration (Figure 1C). In time-laps microscopy we 
verified that higher nanocomplexes concentration, 300g/ml, reflected faster uptake 
(2-5 minutes) then lower concentration, 10g/ml, (15-30 minutes). Nanoparticles 
fluorescent signal, at fixed concentration of 300g/ml, was visible inside the cells as 
nano-sized dots, within 5 minutes, and increased proportionally into the first 15 
minutes, reaching slowly a saturation point at 60 minutes. The whole process can be 
visualized in a video clip provided as Additional file 1 and confirmed by FACS 
analysis (Figure1E). 
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Figure 1. Uptake of Coumarin 6 labeled NPs (1h). PEI-NPs and AcPEI-NPs confocal micrographs 
showed similar uptake efficiency in human primary osteoblasts,  respectively in A and B. Figure 1C 
shows higher magnification 63x,  zoomed 2,5x, of cytoplasmic AcPEI-NPs. Representative images of 
four replicates are shown. D,E) FACS analysis results, evidencing  the kinetic of AcPEI-NPs in 
comparison with PEI-NPs: left, based on the increase in concentrations, right, based on different time-
points. 
 
Uptake mechanism studies were then developed, in order to understand the 
intracellular  trafficking of AcPEI-NPs. The narrow NPs size profile (105+/- 1.5 SD) 
and the hydrophilic composition suggested a role of endocytosis, an energy 
dependent mechanism. Considering the fast internalization, the inhibition studies 
were performed with AcPEI-NPs concentration of 300g/ml, with specific inhibitors 
pre-treatment of clathrin-mediated endocytosis and  caveolae-mediated endocytosis 
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(Figure2). Cell incubation at 4 °C reduced AcPEI-NPs uptake of ~80%, confirming 
the involvement of an energy dependent process, since low temperature decrease 
membrane flexibility and selectively block energy dependent processes [14][15]. To 
understand in details the pathway involved, hOB were incubated with 
Chlorpromazine (Cpz) a clathrin-mediated endocytosis inhibitor [16] and Filipin  III 
(F III) an inhibitor of caveolae formation [17]. Cpz and F III reduced by ca. 70% and 
50%, respectively, intracellular relative fluorescence unit (RFU), and as shown in the 
quantitative histogram in Figure 2, a synergic inhibitory effect of ~ 95% was 
observed, when cells were incubated with both Cpz an F III.  
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Figure 2. Inhibition studies of AcPEI Cumarin6-loaded NPs. The uptake was evaluated by 
densitometry quantification of cell fluorescence in fluorescence microscopy, following 
inhibitors incubation. Low temperature (4 °C) significantly decreased NPs internalization in 
human primary osteoblasts, demonstrating the activation of an energy dependent process. 
Specific inhibitors Chlorpromazine (CPZ) and Filipin III (F III), significantly reduced 
fluorescent AcPEI-NPs intracellular detection, revealing the activation of both clathrin-
dependent and caveolae-dependent endocytosis.  
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Being aware of the activation of endocytosis in AcPEI-NPs uptake, intracellular 
localization with specific markers of early endosomes, RAB5 and lysosomes LAMP1 
were performed in confocal microscopy by immune-fluorescence assay. Confocal 
micrographs showed, after transfection of 1 hour, that AcPEI-NPs co-localize with 
early endosomes (Figure 3A), but not with lysosomes (Figure 3B), confirming an 
initial  incorporation in endosomes, mediated by endocytosis, that in both clathrin-
mediated pathway and caveolae-mediated pathway does not conclude in lysosomal 
degradation. Considering that the final target destination of gene/siRNA delivery is, 
respectively, nuclear and cytoplasm targeting, endosomes escape is successfully 
reached by our system. This result is an important conclusive step, that suggest the 
conserved ability of AcPEI to activate at intracellular level the proton sponge effect 
and this can explain the maintained successful GFP gene delivery, obtained in our 
previous work, in endothelial cells. 
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Figure 3. A, B - Confocal microscopy images showing  colocalization of  AcPEI  Coumarin 
6 loaded nanoparticles (green) with early endosomes RAB5
+
(red) and lysosomes LAMP
+
 
(blue). Important colocalization with endosomes is shown in A as yellow colocalized dots, 
while no  accumulation in lysosomes has been observed in B. 
 
Cytotoxicity of AcPEI-NPs in hOB 
Cell biocompatibility, following nanoparticles transfection, was evaluated in terms of 
necrosis or apoptosis activation. Lactate dehydrogenase (LDH) activity in cell 
surnatant revealed that AcPEI, at the highest concentration used (300 g/ml) does 
not affect cell membrane integrity and cell viability after long term incubation (5 
days), showing levels of LDH activity comparable to the untreated control. Also PEI-
NPs did not show any signal of necrosis in cells, as shown in Figure 4.  
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Figure 4. LDH assay of hOB after 6, 24, 72 and 120 hours of exposure to 300 g/ml of PEI-NPs and 
AcPEI-NPs. Non transfected control cells were tested in parallel to the treated groups. The results are 
expressed as percentage of LDH activity values obtained with the positive control, treated with 
TritonX100 surfactant 0,05%. The results showed at all the time points tested low levels of LDH 
release from hOB, indicating membrane integrity. The percentage values are representative of mean 
±SD of 5 separate experiments. *Statistically significant compared to control p<0.05. 
 
Likewise, in order to exclude the activation of the programmed cell death 
(apoptosis), Western blot analyses were performed to quantify the expression of Bax 
family proteins and Bcl-2 protein levels, calculating the ratio of pro-apoptotic and 
anti-apoptotic signals in the cells. Caspase9 activation was also tested, knowing that 
the induction of the stress signalling pathways JNK/SAPK causes release 
of citocrome C and formation of apoptotic bodies,  through the cleavage of the pro-
enzyme of caspase-9 into the active form. Figure 5A shows Bax / Bcl-2 ratio that 
resulted comparable to untreated control for cells treated with AcPEI-NPs, while a 
little increase in pro-apoptotic balance was observed with 300g/ml of  PEI-NPs. 
Figure 4B reveals that both nanoparticle formulations do not induce a significant 
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Figure 4. Western blot analysis of Bax and Bcl-2 (A) and of pro-caspase 9 and caspase 9 (C) on 
untreated cells (CTR), cells treated with H2O2, (CTR+) and nanoparticles PEI-NPs and AcPEI-NPs, at 
the concentration of 300μg/ml. The images are representative of experiments performed in triplicates. 
B, D) Densitometry measurements were normalized with endogenous tubulin protein expression and 
indicated as Bax/Bcl2 and  pro-caspase9/caspase9 mean values ± SD. No pro-apoptotic index was 
observed with AcPEI-NPs, while a little increase in the pro-apoptotic balance was observed with PEI-
NPs, *statistically significant compared to control p<0.05. 
 
Effects of AcPEI-NPs on hOB differentiation  
The impact of AcPEI-NPs on hOB differentiation was investigated by measuring the 
activity of alkaline phosphatase (ALP), collagen synthesis, mineralization and 
expression of differentiation markers, like osteopontin (OP), osteocalcin (OC) and 
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nuclear factor-kappaB ligand (RANKL).  
We analyzed first the activity of ALP, that resulted increased, compared to untreated 
control, at longer incubation time ≥ 8 days, with AcPEI-NPs at concentrations ≥ 50 
g/ml. From day 8 to day 24 after transfection, the statistical relevance between 
AcPEI-NPs at 300 g/ml and PEI-NPs 300 g/ml increased (Figure 6). Alkaline 
phosphatase activity is greatly enhanced in proliferating osteoblasts during bone 
formation and it is considered an early marker of osteoblast differentiation. ALP 
interacts with bone collagen matrix and  processes pro-collagen to collagen to finally 
lead to matrix mineralization in vitro [18][19]. 
 
 
Figure 6 – ALP activity at different time-points and different concentrations of AcPEI-NPs and PEI-
NPs. Results are expressed as percentage of p-nitrophenol activity of the negative control, represented 
by cells without NPs treatment. The calculated value resulted the average of three experiments (mean 
± SD) performed in duplicate for each NPs concentration (5, 50, 300 µg/ml) and for each incubation 
time (4, 8, 16 and 24 days).  
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Collagen I (COLI) matrix production is another marker of the early stage of 
osteoblast differentiation and COLI synthesis was, therefore, tested by Sirius red 
staining, by light microscopy for qualitative evaluation and by spectrophotometry for 
quantitative measurement. Cells were stimulated for 3 days with PEI-NPs and Ac-
PEI-NPs (300 g/ml) and vitamin D3 (1,25(OH)2D3) 10
-8
M was used as positive 
control. 1,25(OH)2D3 induced wide areas of bone collagen matrix formation in light 
microscopy (Figure 7A), compared to the small areas shown in untreated negative 
control (Figure 7B). The plates stimulated with NPs showed a collagen synthesis 
comparable to the negative control, with no significant differences between the two 
NPs formulations (Figure 7C and 7D). The samples, after the elution of the dye, were 
quantified with the spectrophotometer and the absorbance values confirmed the 
absence of significant COL1 synthesis by NPs (Figure 7E). 
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Figure 7. Light microscopy images of hOB stained with Sirius Red. (A)  positive control 
stimulated with 1,25(OH)2D3 (CTR+); (B) untreated negative control (CTR-),  (C) cell 
stimulated with PEI-NPs  or (D) Ac-PEI-NPs. (E) Ratio of quantitative evaluation of Sirious 
Red staining, normalized for cell density. 1,25(OH)2D3 resulted significantly increase 
collagen matrix production *p < 0.05, respect to PEI-NPs and Ac-PEI-NPs, which showed 
comparable collagen production of untreated control.  
 
Latest stages of hOB differentiation were tested in terms of mineralization and 
specific differentiative markers expression. The effect of NPs in inducing 
mineralization was measured after NPs incubation of 21 days and results are reported 
in Figure 8 as percentage of mineralization normalized to negative control, that was 
considered as 100%. Dexamethasone, a synthetic glucocorticoid involved in the 
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formation of mineralized bone nodules in vitro [20], was used as positive control in 
the experiment and both nanoparticles have shown comparable calcified matrix of 
untreated cells.  
 
 
Figure 8. – Quantitative measurements of osteoblast mineralization in vitro. Confluent human 
osteoblasts, cultured with ascorbic acid and β-glycerolphosphate, were treated with different 
concentrations of the tested nanoparticles PEI-NPs or AcPEI-NPs for 21 days. The formation of 
mineralized nodules was detected on cells by calcein staining. Photomicrographs were obtained by a 
digital Leica camera connected to the fluorescence microscope and quantitative analysis of 
mineralized nodules was performed by measuring the surface of mineralization areas on a computer-
assisted image analyzer. Results represent the average ± standard deviation (SD) of three independent 
experiments. *p < 0.01 vs. negative control. 
 
In order to complete the differentiation studies, real-time PCR was performed to 
investigate the expression of osteopontin (OPN), a marker for middle stage differ-
entiation, and the expression of osteocalcin (OC), a marker for late stage 
differentiation. Experiment was conducted at the time-point of 8 days, with hOB 
treated with PEI-NPs or Ac-PEI-NPs (300 g/ml) and dexamethasone as positive 
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control (Figure 9). We obtained, accordingly with the mineralization studies, 
statistically relevant mRNA levels of OPN in cells treated with 1,25(OH)2D3, ~ 4 
times more than the negative control. Nevertheless, the expression of OPN, increased 
also in cells treated with both NPs types, showing two times higher mRNA than 
untreated control, without significant differences between the two formulations.  
Considering the expression of OC, a protein involved in bone mineralization and 
calcium homeostasis in the final stage of differentiation, only 1,25(OH)2D3  
demonstrated ability in increasing mRNA expression level, 293 times higher than the 
negative control (Figure 9B). From our study, therefore, PEI-NPs and Ac-PEI-NPs 
did not activate the expression of OC. 
For last, but not less important, we evaluated the mRNA expression level of 
RANKL, protein belonging to the superfamily of cytokines, inducing maturation, 
differentiation and activation of osteoclasts. This protein is produced by mature 
osteoblasts and induce the differentiation of osteoclasts by a signal transduction 
pathway, activated by the contact between the secreted RANK-L protein and the 
receptor on the membrane of osteoclasts. Real time PCR showed that AcPEI-NPs, do 
not induce RANKL expression, despite a little activation , ~ 2 fold over control, was 
induced after transfection with PEI-NPs. Cell stimulation with 1,25(OH)2D3 
confirmed that osteoblasts differentiation is accompanied by activation of 
osteoclasts, showing RANKL mRNA expression levels 16.7 times higher than the 
negative control, which can interfere with bone regeneration, causing bone disruption 
(Figure 9).  
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Figure 9. - Real time PCR expression of osteopontin (OPN), osteocalcin (OC) and RANKL in hOB 
stimulated with PEI-NPs and Ac-PEI-NPs. The results are shown as mRNA quantification level, 
expressed as fold over untreated control, for the markers of differentiation tested: A) OPN; B) OC; C) 
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Gene therapy, through the delivery of foreign genes or antisense oligonucleotides to 
inhibit the expression of an endogenous protein, is a promising approach and in some 
cases the only alternative to cure hereditary monogenic diseases, viral infections and 
cancer. This work was focused in improving polyethylenimine (PEI)-based 
nanocarriers, considering the unique capability of PEI in nucleic acids complexation 
and delivery to cells, avoiding lysosomal degradation. The polymer structure, rich in 
positive charged amino groups, allows the efficient electrostatic interactions with the 
phosphate groups of DNA/siRNA and regulate the attraction to the cellular 
membrane for nanoparticles internalization. The disadvantage of PEI, as widely 
known, is the cellular cytotoxicity that is also linked to the high density of positive 
charges and the non biodegradability, limiting its utilization in vivo for aggregation 
with erythrocytes and serum proteins and immune system activation. The 
genotoxicity of nanomaterials is often neglected, but of fundamental importance for 
the large use of nanomaterials in cosmetic products, orthopedic implants and drugs 
and nucleic acids delivery systems. Although the extensive use of PEI as gene 
delivery agent, the genotoxicity of the polymer has not been deeply investigated so 
far. In our work we conducted an extensive study of the toxicity of PEI 
nanoparticles, focusing on cytotoxicity, genotoxicity and immunotoxicity, being 
aware of DNA aberrations and mutations that can lead to carcinogenesis. The 
genotoxic effect of PEI resulted particularly relevant with induction of DNA 
fragmentation and oxidization of DNA bases, sister chromatide exchange and 
micronuclei formation. Revising the literature, it is known that nanoparticles can 
cause direct or indirect DNA damage. Direct contact with the genome is mainly 





regulated by the nuclear pore sizes and nanoparticles of 100 nm are considered too 
big to cause a direct alteration of the genome. Rather, an indirect DNA damage 
mediated by oxidative stress in cells was investigated. Radical oxygen species (ROS) 
are known to cause indirect DNA strand breaks, sister chromatide exchange and 
mutations, thereby the observed increase in the production of radical oxygen species 
(ROS) by cells transfected with PEI-NPs suggested a role of ROS in mediating 
genotoxicity. Immune system activation resulted negligible considering the release of 
pro-inflammatory cytokines, but peripheral monocytes, activated by the exposure 
with PEI-NPs, resulted enhancing the levels of ROS, which can contribute to the 
oxidative stress in cells. In order to improve PEI gene delivery system, we firstly 
developed an alternative nanoparticles formulation, preserving the copolymerization 
with PLGA, where PEI backbone was modified with acetylation of 50% of the amino 
groups. The new formulation AcPEI-NPs resulted a compelling alternative of PEI-
NPs, able to reduce cytotoxicity, genotoxicity and immunotoxicity of unmodified 
PEI, maintaining unaltered transfection and gene expression efficiency in cells. 
AcPEI,  from our study, formed nanoparticles of comparable size of unmodified PEI 
and the reduction in zeta potential did not affect the capacity of condensing plasmid 
into polyplexes and the uptake efficiency in endothelial cells and osteoblasts. 
Moreover, gene delivery efficiency, evaluated through GFP expression in endothelial 
cells, resulted increased with AcPEI-NPs.  
The uptake mechanism in cells was studied in order to understand the intracellular 
trafficking of NPs. Specific inhibition of NPs uptake at 4°C indicated the activation 
of endocytosis, and inhibition studies with specific inhibitors demonstrated the 
involvement of either clathrin mediated pathway and caveolae mediated pathway. 
Intracellular trafficking of nanoparticles is an important feature to establish: for 
instance, involvement of endosomes requires nanoparticles escape from these 





structures in the cytoplasm for gene therapy purpose. More in details in our study, 
AcPEI-NPs colocalized with early endosomes, but absence of accumulation in 
lysosomes was observed. This evidence could be correlated with unaltered ability of 
PEI to activate the ―proton sponge‖ effect that leads to endosomes escape. After 
having demonstrated the higher biocompatibility of AcPEI-NPs with conserved 
capacity of cellular transfection, we investigated the possibility to utilize AcPEI-NPs 
to transfect  human primary osteoblasts for future application in gene and siRNA 
delivery, to promote bone regeneration and/or inhibiting ossification of blood vassels 
in vivo. In particular, we tested in comparison the effect of AcPEI-NPs and PEI-NPs 
on osteoblast differentiation and mineralization, to evaluate a possible effect of PEI 
acetylation. We observed that AcPEI-NPs significantly improved ALP activity, early 
marker of osteoblast differentiation, rather than PEI-NPs, but further investigations 
demonstrated that the latest stages of the  differentiation process are not induced by 
nude NPs. Future applications, a part the delivery of known growth factors genes, as 
BMPs for bone regeneration, are directed to inhibit the calcification of vasculature 
that occurs in diseased conditions, as atherosclerosis. The idea is to develop with 
AcPEI-NPs a novel therapeutic approach to prevent, stabilize or reverse ectopic 
arterial calcifications, based on specific siRNA delivery directed to cells of the 
vasculature wall (such as smooth muscle and endothelial cells). The nanoparticles 
will be tested with traditional cell culture assay in vitro and atherosclerotic dynamic 
model ex vivo. 
 
We created, subsequently, a second nano-formulation based on bPEI, trying to 
improve the targeting and the efficiency of the system in the delivery of siRNA. 
Serum proteins have been recently discovered to serve as endogenous targeting 
ligand and for increasing nanoparticles circulation, after injection. For example, 





apolipoprotein A-I, a component of the high density lipoprotein (HDL), can be 
assembled with liposomes to address siRNA delivery to the liver, through specific 
receptor-mediated internalization in hepatocytes.  
In this study, we have considered a possible use of human serum albumin (HSA) to 
complex with pre-formed bPEI-siRNA complexes, to improve the targeting to 
tumors, for anti-cancer application. Evidences have demonstrated that albumin 
accumulates in tumors by the enhanced permeability and retention (EPR) effect and a 
specific trans-endothelial transportation, and is a promising candidate as a carrier for 
anti-cancer drugs. Abraxane®, an albumin conjugated nanoparticle have already 
demonstrated the role of albumin in enhancing delivery and efficiency of paclitaxel 
in breast metastatic cancer in vivo.  
In our system, electrostatic forces regulated the interaction of HSA with the 
polyplexes, forming a ternary complex. The incorporation of HSA resulted clear for 
the dramatic increase in size of the complexes, about 10 times more of the 80-90 nm 
of bPEI-siRNA polyplexes, but despite of the submicron size, the ternary complex 
resulted more efficient in siRNA uptake and gene silencing in endothelial and 
epithelial breast cancer tumor cells. Smooth association of smaller polyplexes, 
mediated by albumin, is a possible reason of the increased amount of intracellular 
siRNA, resulted important for activating the RNAi mechanism. From our study, it is 
evidenced an important correlation between uptake efficiency and Turbo-GFP 
silencing in cells. HSA-bPEI-siRNA complexes, being internalized by cells more 
efficiently than bPEI-siRNA, resulted able to activate the RNA interference (RNAi) 
pathway. The low gene silencing of unmodified polyplexes can be attributed to the 
inefficient siRNA internalization.   
The study of the uptake mechanism of the complexes was conducted with special 
inhibitors of clathrin and caveolae mediated endocytosis and revealed a major 





activation of caveolae mediated pathway, the same pathway involved in albumin 
uptake in endothelial cells. Speculations of Abraxane® effectiveness suggested a 
specific receptor caveolae-mediated mechanism, enhanced by albumin in tumor 
microenvironment, but the mechanism is still partly unclear. From literature, gp60 
receptor, in caveolae structures, has been demonstrated to mediate albumin 
transcytosis through endothelial cells and the extracellular protein SPARC seems to 
be involved in the uptake in tumor cells. Our study clarified that also breast 
metastatic cancer cells internalized the complexes by caveolae, giving that MDR 
cells and endothelial cells are known to overexpress caveolae. To investigate more in 
detail a specific role of HSA in the uptake of the ternary complex, we carried out 
studies in presence of excess of albumin, as in FBS complete medium, and BSA 
resulted competing with the internalization of the complexes. Furthermore, the 
substitution of HSA with BSA in the ternary complex, in serum-free medium 
transfection, reduced the efficiency of uptake.  
The role of HSA in improving the efficiency of PEI-siRNA polyplexes is therefore 
clear and the system resulted a promising strategy for the delivery of siRNA for in 
vitro studies. The knockdown efficiency, similar to lipoplexes formed with 
Lipofectamine2000, was exceeded by HSA-bPEI-siRNA increase in cell viability 
after transfection. However, no contribution in cell viability was conferred to PEI-
siRNA polyplexes, despite the high difference in siRNA delivery.  
Therefore, HSA-PEI-siRNA polyplexes resulted to be an efficient transfection agent 
in epithelial cancer cells and endothelial cells, but the application in vivo could be 
limited by the uptake competition with HSA and the big size profile of the 
complexes.  
Further studies could be direct to elucidate the role of albumin as targeting molecule, 
investigating, for example, the involvement of the receptor gp60 in the uptake of the 





ternary complex, being aware that HSA could also offer the advantage of immune 
tolerance and  increased bloodstream circulation half-life to nanocomplexes. 
Concluding, this thesis offers some line of research, from reduction of cytotoxicity to 
improvement of cell targeting of nanocarriers, and some interesting results that can 
encourage further studies in optimizing DNA/siRNA delivery systems to be utilized 
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